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Abstract
The study of genetic factors in human diseases has become a central part of medical
research. Non-synonymous single nucleotide variants (nsSNVs) in coding regions of the
human genome alter a protein’s amino acid sequence and thus, are frequently associated
with pathogenic phenotypes. For Mendelian disorders, where a variation in one single
gene is causative, various disease-causing genes with corresponding nsSNVs have been
identified already. Common or complex diseases such as diabetes or cancer, however,
are caused by a varying number of genetic variants modulating a disease’s severity and
type. Furthermore, a human individual inheres more than one nsSNV. Especially the
individual combination of nsSNVs may play a fundamental role in clinical diagnostics to
tailor patient-specific treatment. Methods to study these, though, are currently limited.
In this thesis, we present bioinformatic approaches to analyze putative synergetic effects
of nsSNV sets and identify candidates for disease relevance. First, we performed a
preliminary inventory of current analysis methods, their capabilities as well as their
contribution to medical research, and in particular, their shortcomings. Based on
these findings and additional next-generation sequencing (NGS) studies, we developed
approaches covering the two main scenarios: multiple nsSNVs in one gene and nsSNVs in
multiple genes, respectively. With the presented software tool BALL-SNP, we combine
genetic and structural information in a three-dimensional visualization to enable the
assessment of nsSNV sets in a single gene for diagnostic candidate identification. To
study the functional impact of nsSNVs in multiple genes, we constructed a multi-scale
pipeline comprising 3D content, interaction information and functional cascades of
nsSNV-inherited genes and their encoded proteins.
The developed approaches have been used to analyze a high-quality, clinical data set of
dilated cardiomyopathy (DCM) patients. In consequence, we have been able to identify
nsSNV sets putatively contributing to DCM and consequently demonstrate the ability
of the thesis to promote nsSNV analysis towards computational diagnostics.

German Abstract
Das Studium genetischer Faktoren bei humanen Erkrankungen hat sich zu einem zentra-
len Punkt in der medizinischen Forschung entwickelt. Nicht-synonyme Einzelnukleotid-
Varianten (kurz nsSNVs) in kodierenden Bereichen des menschlichen Genoms vera¨ndern
die Aminosa¨uresequenz eines Proteins und stehen somit ha¨ufig in Zusammenhang mit
pathogenen Pha¨notypen. Bei Mendelschen Erkrankungen, die auf dem Defekt eines
einzelnen Gens beruhen, konnten bereits einige kausative Gene identifiziert werden.
Komplexe Erkrankungen wie Diabetes oder Krebs allerdings werden von einer Vielzahl
genetischer Varianten, die Schweregrad und Art einer Erkrankung beeinflussen, verur-
sacht. Zudem tra¨gt ein Mensch mehrere nsSNVs in seinem Genom. Aus medizinischer
Sicht ko¨nnte gerade diese individuelle Kombination von nsSNVs eine fundamentelle
Rolle hinsichtlich patientenspezifischer Therapien spielen. Methoden, um diese Kombi-
nationen zu analysieren, sind zur Zeit allerdings limitiert.
In der vorliegenden Arbeit stellen wir Ansa¨tze der Bioinformatik vor, um nsSNV
Kombinationen zu untersuchen, synergetische Effekte zu detektieren und Kandidaten
zu identifizieren, die mo¨glicherweise krankheitsrelevant sind. In einem ersten Schritt
wurden bestehende Methoden zur Pathogenita¨tsvorhersage einzelner nsSNVs bezu¨glich
ihrer Sta¨rken und Schwa¨chen sowie ihrer medizinischen Relevanz untersucht. Basierend
auf diesen Ergebnissen und weiteren Next-Generation Sequencing (NGS) Studien wur-
den Methoden entwickelt, deren Fokus auf der Analyse der folgenden beiden Szenarien
liegt: Mehrere nsSNVs in einem einzelnen Gen sowie nsSNVs in mehreren Genen. Die
entwickelte Software BALL-SNP kombiniert genetische und strukturelle Informationen
in einer drei-dimensionalen (3D) Darstellung und ermo¨glicht somit die Bewertung
von Kombinationen aus nsSNVs in einem einzelnen Gen bzw. dem kodierten Protein
hinsichtlich ihrer krankheitsassoziierten Relevanz. Um auch den pathogenen Einfluss
von nsSNVs in mehreren Genen untersuchen zu ko¨nnen, wurde ein Mehrskalenansatz
entwickelt, der 3D Inhalte, Interaktionsinformationen und funktionelle Kaskaden von
Genen mit nsSNVs sowie den kodierten Proteinen umfasst.
Die in dieser Arbeit vorgestellten Methoden wurden verwendet, um einen hochqualitati-
ven klinischen Datensatz an Dilatativer Kardiomyopathie (DCM) erkrankter Patienten
zu analysieren. Dadurch war es mo¨glich nsSNV Kombinationen zu identifizieren, die
mo¨glicherweise kausativ zur Erkrankung an DCM beitragen. Insbesondere konnte damit
gezeigt werden, dass die vorliegende Arbeit einen wichtigen Teil zur Analyse von nsSNVs
bezu¨glich computergestu¨tzter Diagnostikverfahren beitra¨gt.
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1 Introduction
In the last decade, rapid development and advances in experimental high-throughput
techniques like next-generation sequencing (NGS) have enabled the reliable detection
of individual sequence variants in the human genome [1]. Along with computational
methods, NGS allows the discovery and genotyping of hundreds to thousands of genetic
variants in different species, while becoming less expensive. Figure 1.1 illustrates the
course of this trend.
Abbildung 1.1: In the last decade, genome-wide sequencing techniques achieved both,
higher throughput and significant cost reduction [based on the National
Institutes of Health (NIH)].
Since the sequencing of an individual’s whole genome becomes affordable and less
time-consuming, clinicians can get more and more access to genetic data to customize
medical treatment. In particular, understanding the genotype-phenotype relationship is
expected to promote diagnosis, treatment, and prevention in health care [2]. Knowing
the genetic basis of a disease may permit the early detection of patients with a high
risk of developing this particular disease.
An extensive number of genetic variations can be identified in whole genome sequen-
cing studies. Genetic alterations such as non-synonymous variants, for example, are
known to play a critical role in human diseases [3]. Although only a small fraction of
genetic variations are non-synonymous single nucleotide variants (nsSNVs), over 85%
of such mutations are associated with a specific disease [4]. NsSNVs refer to single base
changes in DNA coding regions altering a protein’s amino acid sequence. A pathogenic
1
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phenotype may arise when an amino acid substitution affects structurally important
residues and sites relevant for function, such as residues in catalytic sites of enzymes.
Experimentally gained knowledge about genetic variations is deposited and curated
in different databases, where the Single Nucleotide Polymorphism Database (dbSNP)
currently refers to the largest database concerning SNV annotation with 29,901,117 de-
posited SNVs (dbSNP build 138) [5]. The most popular database for known pathogenic
mutations denotes the Human Gene Mutation Database (HGMD), a comprehensi-
ve repository of mutations associated with human inherited diseases [6]. At present,
94,860 disease-associated nsSNVs are published in the HGMD [7]. Due to the advent of
high-throughput variant detection, though, the amount of identified nsSNVs is growing
rapidly.
To gain knowledge concerning the pathogenicity of nsSNVs via experimental analysis
is laborious and time-consuming, and often even not possible. Thus, computational
approaches have been developed to study the functional impact of nsSNVs in silico. To
date, genome-wide association studies (GWAS) are commonly performed to assess the
statistical association of genetic alterations with common diseases [8]. GWAS compare
regions of the genome between cohorts to identify common genetic variants, statistically
associated with a trait. Although hundreds of GWAS on particular genetic variations
and various diseases have been conducted today, GWAS is susceptible to many limitati-
ons. The application of GWAS, for example, requires large sample sizes, which are often
not available. Multi-marker approaches considering nsSNV combinations in GWAS are
of high complexity increasing the curse of dimensionality. Furthermore, GWAS ignore
known disease pathobiology and prior biological knowledge, however, the inclusion of
this information into data analysis may improve the results [9]. Most nsSNVs discovered
in GWAS have been recognized not to reveal the genetic basis of disease susceptibility
and etiology. In consequence, the majority of these nsSNVs are not suitable to improve
medical health care by genetic testing.
Due to these limitations, prior knowledge about the investigated disease is used to
concentrate on target genomic regions including genes previously associated with the
disease to identify causative variants. Methods to predict the pathogenicity of inherited
nsSNVs cover a wide range of ideas from evolutionary and sequence-based predictions
to detailed atomic energy-based methods [10]. In the following, we summarize the basic
ideas of available computational approaches using different algorithms and features to
predict whether an nsSNV is disease-associated or not.
The majority of the existing computational approaches predict the pathogenic effect
using statistical methods, machine learning techniques or protein evolution models,
based on derived features [11]. These features correspond in general to sequence ho-
mology, biochemical properties and structural information (hydrogen-bond network,
solvent accessibility, etc.). Besides, there are computational methods based on potential
energy functions, force fields and molecular dynamics, which analyze the change in a
protein’s stability, dynamics and interactions to consequently derive the impact of an
2
amino acid substitution [12][13]. These methods, however, can also be time-consuming
and are generally used for small-scale investigations [14].
Among others, the main problem of all these approaches refers to the ’one-SNV, one-
phenotype’-paradigm. For Mendelian disorders, where variation in a single gene is
responsible for the phenotypic consequence, thousand such causative genes have be-
en identified already [15]. Detecting the causative genes in common diseases such as
hypertension, diabetes or cancer, however, still remains a challenge. In general, these
diseases are caused by a varying number of genetic alterations and are influenced by
environmental factors that modulate the severity and type of disease-related pheno-
types [16]. Several nsSNVs in a single gene may exert a synergetic effect on a protein’s
function, whereas a phenotype can also result from combined action of nsSNVs in many
genes [17]. In consequence, the assumption of nsSNVs as single entities, independent
from each other, may not substantially contribute to the improvement of computational
diagnosis, especially for common diseases. Furthermore, from a medical point of view,
especially the individual combination of nsSNVs may play a crucial role in clinical
diagnostics regarding personalized medicine, since genetic variations have been identified
to influence selection, dosing and adverse events of medical drugs [18].
In this work, we focused on the development of approaches to assess the phenotypic
impact of multiple nsSNVs, so-called nsSNV sets, on disease phenotypes and propose
strategies to analyze putative synergetic effects. To the best of our knowledge, compu-
tational methods to predict disease association for nsSNV sets are currently limited.
Figure 1.2 gives an overview of the main analysis strategies developed in this thesis.
In order to analyze the current potential of single nsSNV pathogenicity prediction, we
first performed comprehensive evaluation studies on both, prediction concordance and
prediction quality of existing tools on a high quality clinical data set of cardiomyopathy
samples.
The choice and quality of test data plays a crucial role and since the coverage rate of
the cardiomyopathy data exceeds classical exome capture studies by several orders of
magnitude, these data were used for several analyses within this thesis. In consequence,
we also studied genetic factors putatively contributing to cardiovascular diseases.
The evaluation study of current single nsSNV pathogenicity prediction strategies revea-
led several drawbacks with respect to performance, congruency, applicability and clinical
relevance. However, we have been able to demonstrate the importance of structural
information when analyzing the functional impact of nsSNVs [11].
A protein’s structure, dynamics and interactions are interrelated. In addition, the
effects of genetic differences on protein function are various [19]. Hence, nsSNVs may
change several properties of a protein, simultaneously. The visual inspection of the
three dimensional (3D) structure of proteins affected by nsSNV-introduced amino acid
substitutions, thus, may reveal crucial insights in effects altering protein function.
Based on the gained information, we developed BALL-SNP - a tool to identify candidate
3
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Abbildung 1.2: In this thesis, we developed approaches to assess the functional impact
of nsSNV sets. The analysis of nsSNV sets comprises two parts: the
analysis of nsSNVs accumulating in one gene and the multi-scale analysis
of nsSNVs inhered in multiple genes.
4
nsSNVs for computational diagnostics. BALL-SNP combines genetic and structural
information, respectively, and in particular, offers a visualization of the generated
information as well as an intuitive user interface. Furthermore, we systematically incor-
porated information retrieval and sophisticated analysis methods, such as e.g. cluster
analysis, to collect and generate crucial information in one tool. BALL-SNP relies
on simple input formats: the output of standard SNP annotation software such as
ANNOVAR or a simple tab-separated input file, which prevents users from substantial
re-formatting.
Analyses of nsSNVs in the cardiomyopathy samples impressively demonstrated the
ability of BALL-SNP to uncover spatial relations and putative synergetic effects intro-
duced by genetic alterations.
Besides the analysis of nsSNV sets in one gene, the study of nsSNVs in multiple genes
may play an important role in computational diagnostics. The genetic basis of most com-
mon diseases refers to multiple genetic factors such as gene-gene and gene-environment
interactions [20]. To study nsSNVs in multiple genes, we furthermore developed a
multi-scale approach integrating 3D context, interaction information and functional
cascades from gene sets with nsSNVs. Since we used data from cardiomyopathy patients,
we were also able to study synergetic effects of nsSNVs related to cardiomyopathy. Our
multi-scale analysis of this data set revealed associated nsSNV combinations in seven
genes, putatively related to cardiomyopathy.
In summary, the impact of nsSNVs in coding genes on the cause and the severity of
a disease has become a key task in human health care. A pathogenic phenotype may
result from nsSNV sets clustering in one single gene as well as from the combination
of nsSNVs in many genes. In this thesis, we developed approaches to address both,
the study of nsSNVs sets in one gene and in multiple genes. BALL-SNP, a freely
available software tool, enables the assessment of the impact of nsSNV clusters on a
protein’s function and stability, and consequently assists the selection of candidate
nsSNVs for experimental validation. Though further improvement is needed to meet
requirements of the clinical application, BALL-SNP already decisively contributes
to existing instruments of candidate nsSNV analysis. The constructed multi-scale
analysis pipeline for nsSNV sets in multiple genes supports the computational study of
cumulative effects and their impact on pathogenicity. We have been able to demonstrate
this on the example of a cardiac phenotype, however, the analysis can be likewise
applied to other diseases such as cancer.
The outline of this thesis comprises: in the next chapter, a summary of important
concepts and methods used for this thesis. Next, we present in chapter 3-5 our findings
concerning the pathogenicity prediction of single nsSNVs, sets of nsSNVs within one
gene and nsSNV combinations in multiple genes. Finally, we discuss our contribution
to the analysis of nsSNVs towards the applicability of NGS data in clinical routine.
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In this chapter, we briefly summarize important concepts as well as already available
information and software tools, applied or included within this work. Since this thesis
aims to represent a bridge between bioinformatic strategies and clinical application
scenarios, we focused on comprehensibility for both, bioinformaticians and clinicians.
2.1 Single Nucleotide Variants
The genome comprises an organism’s complete set of deoxyribonucleic acid (DNA)
[21]. The human DNA resides in the cell nucleus and is organized into chromosomes.
It consists of two strands made up by four types of bases: adenine (A), thymine (T),
guanine (G) and cytosine (C). These bases link into pairs, forming the double-helical
DNA structure. The genetic information is coded in the order of the bases in the strands.
The human genome is composed of about 3 billion base pairs including circa 23.000
genes. Interestingly, only approximately 2% of the genome code for proteins. Three
bases, so-called triplets or codons, code for one amino acid constituting a protein’s
primary sequence. Figure 2.1 schematically illustrates the architecture of the human
genome.
The genome sequences of two individuals are 99.9% identical, the remaining 0.1%
DNA accounts for natural genetic variation between and within populations [22], which
results in different traits or phenotypes. The most common type of genetic variation is
defined as a single nucleotide polymorphism (SNP), a position where two alternative
bases occur with > 1% in the human population [1]. More generally, we speak of single
nucleotide variants (SNVs), if no information about the 1% criterion fit is available.
Figure 2.2 illustrates a SNV.
SNVs may occur in gene coding regions as well as in non-coding or intergenic regions
of the DNA. SNVs not located in protein-coding regions may affect gene splicing,
transcription factor binding or messenger RNA degradation. In the coding region, we
discriminate between synonymous and non-synonymous SNVs (nsSNVs). Synonymous
SNVs do not change the amino acid sequence of the corresponding protein due to the
degeneracy of the genetic code, where several triplets can code for one amino acid (see
Figure 2.3). In contrast, nsSNVs alter the protein sequence. They, for example, can
introduce premature stop codons, consequently producing functionally incompetent
truncated proteins, and hence, may possibly be lethal. The more interesting variations
refer to the viable nsSNVs. They frequently result in a single amino acid substitution
within a protein sequence and thus, can alter protein function comprising folding,
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Abbildung 2.1: The human genome comprises all genetic instructions of an organism.
Abbildung 2.2: A single nucleotide variant (SNV) refers to a single base change within
the DNA.
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stability and binding of other proteins or ligands. From a medical point of view, nsSNVs
in coding DNA can be neutral, associated with a disease by exerting a small effect on a
specific trait, or they can be the cause for a distinct disease [11] [7].
Abbildung 2.3: Due to the degeneracy of the genetic code, particular base changes may
introduce different amino acids, whereas others do not alter the protein
sequence.
2.2 Databases containing nsSNV information
Experimentally gained knowledge about nsSNVs is deposited and curated in different
databases. Table 2.1 lists the main available SNV databases. Due to the raising medical
importance, several databases already aim at annotating genetic variants with phenotype
association as well as structural and functional information on proteins. In the following
paragraphs, we shortly summarize the most important databases, which are also included
in the developed approaches presented in this work (see Chapter 4 and 5).
2.2.1 The Single Nucleotide Polymorphism Database (dbSNP)
The Single Nucleotide Polymorphism Database (dbSNP) is currently the largest database
concerning SNV annotations with 29,901,117 deposited SNVs (dbSNP build 138) [5].
It refers to a general catalog of genetic variations including sequence information
around the variant, descriptions of the population inhering the variant and frequency
information by population or individual genotype. Each record is assigned a reference
identifier, the so-called rs ID, allowing to map variants to external resources or databases.
DbSNP is available at http://www.ncbi.nlm.nih.gov/SNP.
ClinVar Tightly coupled with dbSNP, ClinVar accessions report human variations
and interpretations of the relationship of these variations to human health [23]. It is a
9
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Tabelle 2.1: The table lists currently the most important SNV databases.
Database Description Current status
dbSNP Database of Single Nucleotide
Polymorphisms
29,901,117 SNVs
ClinVar Public archive of relationships
among sequence variation and
human phenotype
156,921 genetic variati-
ons
UniProtKB/SwissProt Protein sequence database in-
cluding experimental results,
computed features and scienti-
fic conclusions
548,872 proteins, inclu-
ding 90,378 variants
HGMD Human Gene Mutation Data-
base of mutations causing in-
herited disease
public: 67,439 nsSNVs,
commercial: 94,860
nsSNVs
freely accessible, public archive comprising genetic variants identified through clinical
testing, research and literature. Entries are labeled according to the variation and its
clinical significance. If information is available, ClinVar classifies genetic variants into
the following categories:
• unkown
• untested
• non-pathogenic
• probable-non-pathogenic
• probable-pathogenic
• pathogenic
• drug-response
• histocompatibility
• other.
ClinVar is available via dbSNP or at http://www.ncbi.nlm.nih.gov/clinvar/.
2.2.2 The UniProt Knowledgebase (UniProtKB)
The UniProt Knowledgebase (UniProtKB) is a very comprehensive data collection
of proteins and their functional information, available at http://www.uniprot.org
[24]. It distincts between manually annotated, reviewed data (Swiss-Prot [25]) and
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computationally analyzed, unreviewed data (TrEMBL). Each record lists core informa-
tion such as amino acid sequence, protein name, etc as well as additional information
about biological ontologies, classifications and cross-references to other data sources. In
addition, the UniProtKB includes a collection of human polymorphisms and disease
mutations assigned according to literature reports on probable disease association,
called HUMSAVAR [26].
2.2.3 The Human Gene Mutation Database (HGMD)
The most popular database for known pathogenic mutations is the Human Gene Mu-
tation Database (HGMD) [6]. The HGMD refers to a comprehensive repository of
mutations associated with human inherited disease. Since its initiation, the HGMD has
become the central disease-associated mutation resource for the scientific communi-
ty. In contrast to other developed data sources collating variant-disease associations,
the HGMD is manually curated to avoid inconsistency as well as biased entries. The
HGMD is available at http://www.hgmd.cf.ac.uk/ in a public version for nonprofit
and academic users, and in a professional, commercial version (HGMD and BIOBASE
GmbH), respectively.
2.3 The Protein Data Bank (PDB)
The developed software BALL-SNP (Chapter 4) critically depends on 3D structures and
is consequently connected to the Protein Data Bank (PDB), the most comprehensive
archive for 3D structural data of biological macromolecules world-wide [27]. The publicly
available archive contains experimentally resolved structures ranging from small peptides
and nucleic acids to large complexes. It is available at http://www.rcsb.org/pdb/.
In addition, the PDB also defines the well-known PDB file format, which contains all
information required for a 3D structure and is used as input in molecular modelling
software as well as 3D visualization tools (see Section 2.8).
2.4 DrugBank - Open Data Drug and Drug Target Database
DrugBank is a freely available bioinformatics and cheminformatics resource (http:
//www.drugbank.ca), which links chemical, pharmacological and pharmaceutical data
to comprehensive sequence, structure and pathway information of their corresponding
drug targets [28].
The current available version 4.2 contains 7,759 drug entries including 1,600 small
molecule drugs, 160 biotech (protein/peptide) drugs, 89 nutraceuticals and over 6000
experimental drugs [29]. Since we focus on the identification of candidate nsSNVs
for computational diagnostics, information about already specified drug targets can
critically contribute to this process.
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2.5 Pathogenicity prediction
Due to the advent of high-throughput variant detection techniques, the amount of iden-
tified nsSNVs is growing rapidly [11]. To gain knowledge concerning the pathogenicity
of nsSNVs via experimental analysis is laborious and time-consuming, and often even
not possible. To solve this intricate problem, various computational methods have been
developed over the past decade using different algorithms and features to predict the
biological impact of nsSNVs on a protein’s function in silico and to assess whether an
nsSNV is associated with a specific disease.
Most of these prediction methods are based on evolutionary information and/or combine
functional and structural parameters as well as multiple sequence alignment derived
information. Conservation information usually is obtained from alignments of homolo-
gous or somehow related sequences, including position-specific profiles. Some prediction
methods also incorporate available annotations, e.g. Gene Ontology (GO) [30] or protein
family information (Pfam) [31]. Because protein structure encodes protein function,
information concerning the three-dimensional (3D) structural environment, such as
solvent accessibility, electrostatics and hydrophobicity, is also a crucial criterion to
assume a variant’s functional impact [11]. Finally, the in silico-derived information
about protein structure and function, including essential properties of both, the original
and the substituted residues, is combined into features. According to these features,
nsSNVs are classified into benign or pathogenic using different machine learning me-
thods such as neural networks, random forests, support vector machines (SVMs) or
Bayesian methods and mathematical operations. Figure 2.4 summarizes this general
scheme of pathogenicity prediction.
Abbildung 2.4: Overview of the general SNV pathogenicity prediction strategy.
Most techniques were trained on data deposited in databases such as dbSNP or
UniProtKB, and with artifically constructed test sets.
In the following, we shortly summarize the underlying principles of prediction approaches
selected for integration in the developed software tool BALL-SNP (see Chapter 4).
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2.5.1 PANTHER - Evolutionary analysis of coding SNVs
PANTHER computes substitution position-specific evolutionary conservation (sub-
PSEC) scores on alignments [32]. These alignments of evolutionarily related proteins
are generated by Hidden Markov Models (HMMs) and collected in the PANTHER
library. The subPSEC score defines amino acid probabilities for the occurrence at
certain positions among evolutionarily related sequences. Classification is done via
scoring a query protein against the entire built PANTHER library, currently comprising
over 38,000 HMMs [33].
The PANTHER library as well as the corresponding software tool is available at
http://pantherdb.org/tools/.
2.5.2 PhD-SNP
PhD-SNP can be divided into two SVM-based strategies: the single-sequence and
the sequence profile SVM [34]. The single-sequence SVM classifies the amino acid
substitution as neutral or disease-linked based on the nature of the substitution and
the properties of the neighboring sequence environment. In addition, the profile SVM
calculates sequence profile information derived from multiple sequence alignments
and classifies the functional impact according to the ratio of wild type and mutant
frequencies of amino acids. Both SVM strategies combined account for the PhD-SNP
prediction result.
The software tool is available at http://snps.biofold.org/phd-snp/phd-snp.html.
2.5.3 Polymorphism Phenotyping 2 - PolyPhen2
Polymorphism Phenotyping 2 (PolyPhen2) predicts the mutational effect by a naive
Bayesian classifier [35]. The used features include both, sequence information derived
from multiple sequence alignments and structure information such as, e.g., solvent
accessibility.
Moreover, PolyPhen2 computes position-specific independent counts (PSIC) profile
scores of two amino acid variants. The PSIC profile is a logarithmic ratio of the likelihood
that a given amino acid occurs at a particular site to the background probability of the
amino acid occurring at random at a given position within the protein sequence [36].
PolyPhen2 is available at http://genetics.bwh.harvard.edu/pph2/.
2.5.4 PROVEAN - Protein Variation Effect Analyzer
PROVEAN calculates a pairwise sequence alignment score based on homologous
sequences [37]. This score measures the sequence similarity change of a query sequence
to a homologous protein sequence before and after an amino acid substitution within
the query sequence. In contrast to most of the other available prediction approaches,
PROVEAN is able to predict the functional influence for all types of protein sequence
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variations, such as insertions, deletions and substitutions.
Additionally, precomputed PROVEAN scores generated in November 2012 for all
possible single amino acid substitutions and single amino acid deletions of human
proteins from Ensembl 66 are freely available at http://provean.jcvi.org.
Figure 2.5 lists the main state-of-the-art pathogenicity prediction tools currently availa-
ble. Besides, there are computational methods based on potential energy functions,
force fields and molecular dynamics, which analyze the change in a proteins stability,
dynamics and interactions to consequently derive the impact of an amino acid substi-
tution [12][13]. These methods, however, can also be time-consuming, since they are
computationally expensive, and are generally used for small-scale investigations [14].
2.6 I-Mutant: Protein stability prediction
Since structural information such as protein stability is important for the assessment
of nsSNVs, we embedded I-Mutant within the BALL-SNP approach developed in this
thesis (Chapter 4) as well as applied this tool within our multi-scale analysis in Chapter
5.
I-Mutant 2.0 is an SVM-predictor based on protein sequence or structure for the
automatic assessment of protein stability [38]. It predicts both, the sign and the value
of a protein’s stability change upon an amino acid substitution.
The sign of the free energy difference, calculated by the substraction of the wild type
free energy from that of the mutant, specifies protein stabilization (negative sign) or
destabilization (positive sign). The main advantage of I-Mutant compared to other
existing protein stability methods is the ability to predict from protein sequence, not
requiring structural information.
2.7 The FASTA format
The FASTA format is a text-based format to represent either the sequence of nucleotides
or peptides, where nucleotides or amino acids are defined as single-letter codes, e.g. H
for Histidine [39]. The FASTA sequence consequently refers to the primary sequence of
the residues on a protein backbone.
The first line of a FASTA file corresponds to the so-called header with description
information such as the protein name and so on. This description line is labeled with a
”>” at the beginning and is optional. A simple example for a FASTA file refers to:
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Abbildung 2.5: Overview of the main state-of-the-art pathogenicity prediction tools
[11].
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>sp|P08588|ADRB1 HUMAN Beta-1 adrenergic receptor
MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQ
QWTAGMGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLL
VVPFGATIVVWGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLA ...
FASTA files are the standard format to represent a protein sequence and thus, are
generally the input for alignment tools and further methods dealing with protein
sequences. The approaches developed in this thesis also require protein sequences and
in consequence, rely on FASTA file information.
2.8 The Protein Data Bank (PDB) File
For the assessment of nsSNVs, 3D structural information of the corresponding protein
with amino acid substitutions introduced by these nsSNVs, is essential. In general, 3D
information derived from X-ray diffraction and Nuclear Magnetic Resonance (NMR)
studies is represented via the Protein Data Bank (PDB) file format [27], created in the
1970’s, and available at the PDB (Section 2.3).
The formatting is defined by the character positions in a line, where each line starts with
left-justified six characters, which denote an identifier for the line type, the so-called
record name. There are various record names specifying available information such as
SEQRES for the protein FASTA sequence (Section 2.7) or HELIX and SHEET for the
secondary structure elements, for example. We concentrate, however, on the ATOM
record, which is the most important one used in this thesis.
The ATOM record corresponds to the atomic coordinates for standard amino acids and
nucleotides. Additional information besides atom name and coordinates such as the
corresponding residue, the residue index and so on are also listed in ATOM lines.
The PDB is a collection of 3D information collected world-wide and although sustained
efforts to maintain high-quality data exist, there are unfortunately inconsistent and
informal PDB files, not fully checked for errors.
Above, we summarized important methods used in the majority of the developed
approaches presented in this thesis. In the following, we describe applied strategies
according to the corresponding approach, which incorporates these.
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2.9 Pathogenicity prediction of nsSNV sets: material and
methods
In Chapter 3, we present the results of an extensive evaluation study of current-state-
of-the-art pathogenicity prediction methods. To evaluate the prediction performance
of the selected tools on a created test set (see Section 2.12.1), we calculated standard
performance measures defined below.
2.9.1 Measures to evaluate statistical performance
Based on the prediction results for the annotated test set (Section 2.12.1), we studied
the prediction performance of the pathogenicity prediction methods by calculating
specificity, sensitivity and accuracy. Specificity measures the proportion of negatives,
that are correctly identified, whereas the sensitivity quantifies the proportion of actual
positives [40], that are correctly detected as such:
specificity = TNTN + FP
sensitivity = TPTP + FN
where TP = true positives, FP = false positives, FN = false negatives and TN = true
negatives.
Besides, the accuracy of a measurement system is the degree of closeness of a quantity
to its actual true value and can be seen as the degree of veracity. It identifies the
proportion of the true results [40]:
accuracy = TP + TNTP + FP + TN + FN
where TP = true positives, FP = false positives, FN = false negatives and TN = true
negatives.
Handling unbalanced data Since the created test set is slightly unbalanced (192
neutral to 147 disease-annotated nsSNVs, details in Section 2.12.1), we also computed
the balanced accuracy and Matthews correlation coefficient (MCC), defined as:
balanced accuracy = specificity + sensitivity2
MCC = (TP∗TN)−(FP∗FN)√
(TP+FP )(TP+FN)(TN+FP )(TN+FN)
where an MCC value of 1 corresponds to a perfect correlation.
Based on the evaluation study of current pathogenicity prediction tools, we depict
in Section 3.2 the attempt to adapt single pathogenicity prediction strategies to the
assessment of nsSNV sets. Important methods used for the definition of scoring methods
to measure the functional effect of nsSNV sets are summarized in the following.
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2.9.2 Amino acid distribution probabilities
The amino acid sequence of a protein is characteristic for a protein’s folding and
function. Minor changes within this sequence may alter or prevent function [41]. To be
able to assess the functional effect of amino acid substitutions introduced by nsSNVs,
we studied the amino acid spectrum as well as the combination of wild type and mutant
residues in neutral and disease-annotated DCM data (see Section 2.12.1). In particular,
we compared the observed frequencies with the expected values determined based on
the distribution of all amino acids in the test set. The expected values are also computed
with regard to codon diversity and the probability to generate a certain substitution
referring to all possibilities for a translation from a specific amino acid to another by
only one triplet base mutation of the wild type codon.
Single amino acid probabilities
In general, the expected and observed frequencies of an amino acid X within a query
protein of a given sequence seq are defined as:
fexp(X) =
#codons(X)
all codons ∗ length(seq)
fobs(X) = #X
(2.1)
where ’#’ refers to ’number of’, #codons(X) denotes the number of available cod-
ons for amino acid X and all codons codes for all codons in the genetic code, namely 64.
Since we are mainly interested in the analysis of amino acid substitutions introduced
by nsSNVs, we explicitly studied the amino acid distributions at wild type and mutant
positions, respectively. At the wild type position of an amino acid sequence the calculated
frequencies are defined as:
fexp(X) =
#codons(X)
all codons ∗#mutations
fobs(X) = #X
(2.2)
where ’#’ refers to ’number of’, #codons(X) denotes the number of available codons for
amino acid X, all codons codes for all codons in the genetic code (64) and #mutations
refers to the number of mutations detected within the particular amino acid sequence.
A nsSNV changes one base within a codon and hence, we calculated the amino acid
distributions at mutant positions in a protein’s sequence with regard to codon diversity
and the probability to generate a certain substitution referring to all possibilities for a
translation from a specific amino acid to another by only one triplet base mutation of
the wild type codon. For the distributions at mutant positions we define:
18
2.9 Pathogenicity prediction of nsSNV sets: material and methods
fexp(X) = codonDiversity(X) ∗#mutations
codonDiversity(X) = #subs(Z
∗−→X)
#subs(all)
fobs(X) = #X
(2.3)
where #subs(Z∗ −→ X) denotes the number of substitutions from any amino acid to
X by one base change and #subs(all) refers to the number of all possible amino acid
substitutions resulting from one base change in the wild type codon.
Amino acid substitution probabilities
Beyond the single amino acid distributions, we also studied the spectrum of combinations
of wild type and mutant residues. An amino acid substitution is defined as X −→ Y ,
meaning amino acid X is substituted by amino acid Y . Based on all mutant residues
MTi, which can result from the observed wild type WT by one base change within its
triplet, the probability to generate certain substitutions WT −→ MTi is calculated.
The expected and observed frequencies of amino acid substitutions in the used data set
are determined with respect to the codon diversity by:
fexp(X −→ Y ) = codonDiversity(X −→ Y ) ∗#mutations(X −→ Y )
codonDiversity(X −→ Y ) = #subs(X−→Y,by 1 base change)#subs(X−→Z|Z 6=Y,by 1 base change)
fobs(X −→ Y ) = #subs(X −→ Y )
(2.4)
where #subs(X −→ Y, by 1 base change) defines the number of substitutions from
amino acid X to Y by only one base change in the triplet of X. In addition, #subs(X −→
Z|Z 6= Y, by 1 base change) denotes the number of all possible substitutions from X to
any other amino acid Z unequal Y by one base change in the triplet of X.
2.9.3 The BLOcks SUbstitution Matrix (BLOSUM)
Since evolutionarily related proteins are supposed to form protein families inhering
similar functions, the ability to measure the similarity of protein sequences is essential
in molecular biology. Typically, alignment methods for protein sequences are applied
to measure this similarity. The BLOcks SUbstitution Matrix (BLOSUM) refers to a
substitution matrix for local sequence alignments of proteins [42]. BLOSUM comprises
blocks of similar sequences and counts the relative frequencies of amino acids and their
substitution probabilities.
To date, several different BLOSUM matrices exist based on the underlying similarity
of the used protein sequences. Matrices labeled with higher values were built on closely
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related sequences, whereas low matrix numbers denote more divergent sequences within
the applied alignments. BLOSUM80, for example, was defined on more than 80%
identical protein sequences. In contrast, BLOSUM62 relies on sequences with more than
62% similarity. BLOSUM62 refers to the default matrix used in the protein BLAST
algorithm (see next subsection).
2.9.4 Position-Specific Iterated BLAST (PSI-BLAST)
The Basic Local Alignment Search Tool (BLAST) compares the biological query
sequence of proteins or DNA with a library or database of sequences to detect similar
sequences based on a specific threshold [43]. According to the query sequence, different
BLAST versions exist, collected in the BLAST package. Among these, the Position-
Specific Iterated BLAST (PSI-BLAST) identifies distant relatives of a protein [44].
PSI-BLAST first combines closely related proteins to a profile sequence based on a
position-specific scoring matrix (PSSM). Next it queries a protein database based on the
generated profile to determine relatives to the query protein with distant evolutionary
relationship.
PSI-BLAST is available within the BLAST package at http://blast.ncbi.nlm.nih.
gov/Blast.cgi?CMD=Web&PAGE=Proteins&PROGRAM=blastp&RUN_PSIBLAST=on.
2.9.5 Position-Specific Scoring Matrix (PSSM)
Sequence similarity search methods using profiles such as PSI-BLAST (Section 2.9.4)
have been recognized to more sensitively detect also weak relationships compared to
strategies based on simple sequence search queries [45]. An applied profile refers to
a so-called Position-Specific Scoring Matrix (PSSM) and encodes which residues are
observed at each position in a sequence alignment of evolutionary related sequences [44].
A PSSM measures the amino acid substitution frequencies amongst a protein family,
and in consequence, enables the assessment of probable amino acid substitutions at
each sequence position of each protein within the family. In addition, it allows the
identification of remote homologues of a protein.
The quality of a PSSM, however, relies on the availability of protein families and the
amount of available evolutionary related sequences.
2.9.6 PSIPRED
Protein structure encodes protein function and thus, the knowledge about 3D structure
elements such as the secondary structure building blocks essentially contributes to
the analysis of proteins, their interactions and putative dysfunctions. To date, the
prediction of secondary structure elements such as helices or beta sheets has become
highly accurate using, for example, the state-of-the-art prediction tool PSIPRED [46].
PSIPRED predicts the secondary structure of a protein via a two-stage neural network,
which is based on PSSMs (Section 2.9.5) generated by PSI-BLAST (Section 2.9.4).
20
2.10 BALL-SNP: material and methods
The prediction process comprises first a generation of a PSSM, next a prediction of an
initial secondary structure sequence and finally a filtering procedure.
PSIPRED is available at http://bioinf.cs.ucl.ac.uk/psipred/.
2.10 BALL-SNP: material and methods
In this thesis, we present the implemented tool BALL-SNP to identify candidate nsSNVs
for computational diagnostics. Details about BALL-SNP are explained in Chapter 4.
Important concepts used within BALL-SNP, are summarized below.
2.10.1 The Biochemical Algorithms Library - BALL
The developed software tool BALL-SNP, presented in Chapter 4, is based on the
Biochemical Algorithms Library (BALL), an application framework for rapid software
prototyping in molecular modelling research and drug design [47]. The overall structure
of BALL consists of several layers, each providing functionality for a well-defined field,
as can be seen in Figure 2.6. In this stratified architecture, top layers depend on lower
ones for their implementation.
Abbildung 2.6: Overview of the BALL framework structure [48].
The basis of all BALL classes is a comprehensive set of Foundation Classes providing
general implementations for advanced data structures (e.g. trees, hash maps), mathe-
matical objects (e.g. matrices, vectors), system classes (e.g. file I/O, networking), or
design patterns of the C++ standard template library [49]. The BALL Kernel contains
the data structures for the representation of molecular entities as for example atoms,
bonds, molecules and proteins. The third layer consists of several basic components,
including molecular mechanics methods, molecular editing, as well as calculation and
visualization of electrostatic properties.
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Besides this algorithmic fundament, BALL also incorporates a graphical front-end for
the visualization of molecular structures, called BALLView [50]. BALLView enables
the availability of BALL’s broad functionality via an integrated user-friendly graphical
user interface (GUI) based on the cross-platform application framework Qt.
In addition, BALL offers a Python scripting interface for rapid prototyping.
2.10.2 Input formats in BALL-SNP
To ensure straightforward usability, we currently offer two different input formats: an
ANNOVAR-based input [51], as well as a simple tab-separated format, the so-called
BALLformat. Hence, users are enabled to adopt the output obtained from standard
SNP annotation software such as ANNOVAR without substantial re-formatting, as
well as use SNV information from different sources compiled in a simple tab-separated
input file (BALLformat). Both input formats are below defined in detail.
BALL-SNP focuses on the analysis of the pathogenic relevance of amino acid substitu-
tions introduced by nsSNVs. The SNP calling and annotation process, however, may
have great influence on the results of the BALL-SNP analysis. In consequence, the user
should carefully adopt the SNP calling and annotation parameters to his application
purpose.
Since 3D structure information is essential for the analysis of amino acid substitutions
aggregating in one single protein and introduced by nsSNVs in the encoding gene, we
automatically extract the PDB identifier of the largest available 3D structure from the
UniProtKB [26]. The chosen PDB structure, then is automatically loaded from the
Protein Data Bank (PDB) [27].
To maintain flexibility, we also provide the possibility to state a preferred PDB identifier
within both input formats or to specify a file name with a user-built 3D model of the
query protein in the first line of the input file. The PDB identifier is marked via the
flag PDB:, whereas an available 3D model file is indicated with the flag FILE:.
ANNOVAR-based input
The used parameters for the ANNOVAR call should be carefully chosen by the user
based on his application purpose. BALL-SNP does not validate the ANNOVAR output.
The file name should end with annovar.txt. Gray-colored text lines in the example
are optional. A single point in columns refers to missing information.
PDB: 2LSQ
Line Effect Gene Chr Pos rs ID ...
13 nsSNV ADRB1:... :p.G389R, chr10 115805056 rs1801253 ...
...
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BALLformat input
This tab-separated format can be manually created by the user and may include
information gained from different annotation sources. The file name should contain
BALLformat.txt at the end. Gray-colored text lines in the example are optional. A
single point in columns refers to missing information.
PDB: 2LSQ
Gene Symbol Transcript SNV Chr Pos rs ID
ADRB1 NM 000684 G389R chr10 115805056 rs1801253
ADRB1 NM 000684 S475A chr10 . .
...
In addition, further input formats can easily be added.
2.10.3 3D molecular modelling
Since the gap between known protein sequences and available 3D protein structures is
still huge and the experimental determination of 3D structures is difficult, techniques
to model the missing 3D information of proteins via computational methods have
been developed. 3D molecular modelling refers to a template-based protein structure
modelling in silico [52].
First, a protein with an available 3D structure and a high sequence identity to the
query/target protein is searched to serve as scaffold on which the 3D model is built
on. In general, this search is performed via multiple alignments of homologous proteins
deposited in databases and also includes external data such as secondary structure
information, known motifs and conserved features.
The template selection usually relies on specific parameter such as sequence identity,
relative alignment length or resolution, while the resolution of an experimentally re-
solved structure implies the accuracy of atomic coordinates. The sequence identity is
calculated by the ratio of matching residues in the pairwise alignment of target and
template sequence. Generally, proteins with more than 35% sequence identity reveal
homology, while below 35% detailed investigations are required.
Next, based on the selected template, a 3D structural model for the target protein is
built. To evaluate the quality of a generated 3D model, various methods are applied,
among these the Discrete Optimized Protein Energy (DOPE) score is calculated [53].
DOPE is a pseudo-energetic score to assess the quality of a structure model. In par-
ticular, negative DOPE scores correlate with native-like models. The quality of the
constructed model, however, critically depends on the quality of the selected template.
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Figure 2.7 summarizes the schematic 3D molecular modelling workflow.
Abbildung 2.7: A schematic overview of 3D molecular modelling [54].
Currently, several software packages for 3D structural modelling are available. One of
the most used approaches is the license-restricted toolkit MODELLER [55].
2.10.4 A Database of Comparative Protein Structure Models (ModBase)
Along with computational methods for 3D molecular modelling (see Section 2.10.3),
databases to collect already generated 3D models have been built. The most prominent
representative refers to ModBase, a database comprising annotated comparative protein
structure models built with the automated modelling pipeling ModPipe [56]. ModPipe
primarily is based on the toolkit MODELLER [55] in terms of fold assignment, sequence-
structure alignment, model building and model assessment.
ModBase currently contains almost 30 million models for about 4.7 million unique
protein sequences and is available at http://salilab.org/modbase.
2.10.5 Hierarchical cluster analysis
To be able to detect nsSNV close to each other and thus, putative additive effects, we
implemented a cluster analysis strategy for nsSNVs.
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The goal of a cluster analysis is to partition an amount of objects into groups (cluster)
in a way, that the pairwise distances between those assigned into one cluster tend to be
smaller than those distributed in different clusters [40].
Hierarchical clustering can be divided into two main strategies: agglomerative (bottom-
up) and divisive (top-down). Divisive methods start at the top with one single cluster
including all data objects and at each level recursively split one of the existing clusters
at the current level into two new cluster. The split is chosen to produce two new groups
with the largest between-group distance.
Agglomerative clustering algorithms start with every object representing a singleton
cluster. At each step, the two clusters with the smallest distance are merged into one
single cluster, sequentially producing one less cluster at the next higher level until all
elements end up in one final cluster.
The criteria to link specific clusters are defined based on the pairwise distances between
the objects in the cluster. They can be divided into three main concepts (see also Figure
2.8):
• Single linkage, also known as nearest neighbor clustering, merges groups accor-
ding to the distance of the nearest members.
• Complete linkage refers to the opposite of the single linkage method, since
groups are merged based on the distance of the most remote pair of member
objects.
• Average linkage defines the distance between the groups as the average of the
distances between all pairs of individual objects in the two groups. It can be
interpreted as a compromise between single and complete linkage methods, and
tends to produce compact cluster.
To measure the distance of two objects a = (xa, ya, za) and b = (xb, yb, zb) in a 3D
space, several common measures have been defined:
• Euclidean distance: dE(a, b) =
√
(xa − xb)2 + (ya − yb)2 + (za − zb)2
• Euclidean squared distance: d2E(a, b) = (xa − xb)2 + (ya − yb)2 + (za − zb)2
• Manhattan distance: dM (a, b) = |xa − xb|+ |ya − yb|+ |za − zb|
2.10.6 The Database of Protein interaction SITEs (PiSITE)
Since the biological functions of proteins are driven by their interactions, the knowledge
about these are fundamental for the analysis of dysfunctions introduced by genetic
variants. The Database of Protein interaction SITEs (PiSITE) collects information
concerning protein interaction sites, multiple binding states of a protein or different
interaction partner [57]. The identification of interaction sites is based on available PDB
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Abbildung 2.8: Example scenarios for the three linkage strategies.
(Section 2.3) protein structures of the same protein, whose binding sites are mapped. In
particular, the collected information is provided at the protein residue level, enabling
the analysis of functional changes caused by amino acid substitutions.
PiSITE offers a web-based interface as well as downloadable flat files. It is available at
http://pisite.hgc.jp.
2.10.7 The Exome Aggregation Consortium (ExAc)
These days, due to the advent of NGS, a lot of sequencing projects are performed to get
insights into the genotype-phenotype relationship. To be able to compare their results
despite of different used calling methods and parameters, a coalition of investigators
founded the Exome Aggregation Consortium (ExAC) [58]. Their goal is to curate and
harmonize exome sequencing data from large sequencing projects and to consequently
provide these data to the scientific community. The raw data of the included sequencing
projects has been preprocessed using the same pipeline, and in particular jointly variant-
called to increase consistency. We also include this information within BALL-SNP
(Chapter 4).
2.11 Multi-scale analysis pipeline: material and methods
In Chapter 5, we present a pipeline for the multi-scale analysis of nsSNV sets. Basic
concepts and databases included within this pipeline are summarized in this section.
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2.11.1 Association rule learning
To discover strong and/or hidden relations between variables in large data sources,
association rule learning is generally applied. Given a set I of n binary items or variables,
association rule learning aims to find joint values of items, that are most frequently in
the data source [40]. These joint values are defined as implications and are formulated
as so-called association rules. A rule ri comprises two different sets of items X and Y :
ri = X −→ Y, (2.5)
where X,Y ⊆ I and X ∩ Y = ∅.
Different measures of significance and interest are applied to quantify the quality of
the generated rules [59]. The most important measures are known as support and
confidence. Support refers to a frequency constraint determining the quantitative
applicability of a rule, while confidence measures its reliability. Support and confidence
are mathematically defined as:
support(X) = |{ri|X ⊆ ri, ri ∈ R}|, (2.6)
where |.| denotes the cardinality of a set and R refers to the set of all generated
association rules.
confidence(X −→ Y ) = support(X ∪ Y )
support(X)
, (2.7)
where support(X ∪ Y ) denotes the support of the union of items in X and Y .
Many algorithms to mine association rules are available, where the methods typically
can be split into two parts:
1. Find all frequent item sets, that satisfy a minimum support threshold specified
by the user.
2. Define association rules based on the frequent item sets, that also fulfill a minimum
confidence constraint defined by the user.
Since association rule learning is a state-of-the-art method in market basket analysis,
we made use of this powerful strategy and transfered the method to genomic analysis
for the identification of associated nsSNV sets in one gene or related nsSNVs in multiple
genes (see Figure 2.9).
In the analysis pipeline presented in Chapter 5, we applied the R package arules [60]
using the implemented apriori algorithm [61]. The confidence threshold was set to 0.8
and different levels of support, starting with at least 0.5, were tested.
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Abbildung 2.9: We transfered the application of association rule learning from the mar-
ket basket analysis to genomic analysis to identify associated nsSNVs.
2.11.2 The STRING database
The STRING database is a comprehensive resource of known and predicted protein
interactions [62]. These interactions comprise direct (physical) and indirect (functional)
associations, and are derived from four sources:
• genomic context
• high-throughput experiments
• conserved coexpression
• previous knowledge (e.g. pubmed)
STRING currently covers 9,643,763 proteins [63]. The database is freely available at
http://string-db.org/.
2.11.3 The Gene Ontology Annotation (GOA) database
The Gene Ontology Annotation (GOA) database provides high-quality Gene Ontology
(GO) annotations for proteins deposited in the UniProtKB (Section 2.2.2). The annota-
tions are generated by automatic predictions and manual curation [64]. The applied
algorithms for automatic annotation are based on sequence similarity, orthology or
domain information as well as existing cross-references and keywords.
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Currently, GOA comprises 368 million GO annotations for almost 54 million proteins
[65].
It is available at http://www.ebi.ac.uk/GOA.
2.11.4 The KEGG database
The use of expert knowledge from e.g. metabolic pathways reveals essential information
for the analysis of gene-gene and gene-environment interactions. The Kyoto Encyclopedia
of Genes and Genomes (KEGG) database refers to a comprehensive resource of metabolic
and regulatory pathways. The KEGG PATHWAY database [66] is a collection of
manually created pathway maps, which represent knowledge on molecular interaction
and reaction networks for
• metabolism
• genetic information processing
• environmental information processing
• cellular processes
• organismal systems
• human diseases.
These informations promote the biological interpretation of higher-level systemic func-
tions. Currently, about 405,927 pathway maps are deposited.
The KEGG PATHWAY database is freely available at http://www.genome.jp/kegg/
pathway.html.
2.11.5 naccess
Solvent accessibilities provide an intuitive and quantitatively reasonable idea of the
complexity of the molecular interaction network an amino acid residue is involved
within a protein [67]. Thus, we also computed solvent accessibilities via naccess [68].
Naccess calculates the solvent accessible area of a protein in a PDB file by defining
a probe sphere rolled around the protein’s surface. The resulting path of the probe
sphere center refers to the solvent accessible surface of the protein. In general, the
probe sphere radius corresponds to the radius of the water molecule (1.4 A˚), however,
naccess also allows user-defined sizes of atoms and the applied probe sphere.
It is freely available at http://www.bioinf.manchester.ac.uk/naccess/.
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2.11.6 LIGSITEcsc
The identification of binding pockets on protein surfaces is crucial for structure-based
drug design applications and protein-ligand docking studies [69]. The LIGSITEcsc is
an extended implementation of the well-known LIGSITE algorithm. Instead of using
atom coordinates, however, LIGSITEcsc relies on the Connolly surface of a protein to
capture surface-solvent-surface events. The identified pockets then are ranked according
to the conservation of the involved surface residues.
It is freely available at http://www.projects.biotec.tu-dresden.de/pocket.
2.11.7 CELLmicrocosmos
CELLmicrocosmos is an integrative cell modelling and stereoscopic 3D visualization
project [70]. To support and visualize the subcellular localization prediction of proteins,
CELLmicrocosmos incorporates a PathwayIntegration (CmPI) component (version:
CELLmicrocosmos 4.2 PathwayIntegration).
CmPI is connected to DAWIS-M.D., a data warehouse containing a number of databases
[71]. It applies a context-based localization prioritization, since each protein usually
can obtain different localization entries from databases.
The CELLmicrocosmos including the CmPI is available at
https://www.cellmicrocosmos.org.
2.12 Used data sets
To be able to analyze existing pathogenicity prediction approaches and develop new
strategies to assess disease susceptibility of nsSNV sets, a reliable data set is highly
required. The data sets used in this thesis split into patient samples diagnosed with
dilated cardiomyopathy (DCM)[72] and healthy control samples from the 1000 genomes
project [73]. Details are presented below.
2.12.1 Cardiomyopathy data set
Due to the valuable contribution of the INHERITANCE Project Group, we were able
to study a data set containing 842 nsSNVs in 76 genes that are clinically relevant
for DCM (known causes and likely candidate genes for DCM) found by studying the
genetics in 639 patients with DCM [72]. DCM refers to a frequent disease of the heart
muscle (myocardium) and as such belongs to the class of cardiomyopathies [74]. Briefly,
the heart’s main pumping chamber in DCM patients thins introducing an impaired
systolic pump function. Recently, genetic variations have been identified to substantially
contribute to DCM [75]. Despite already detected genetic mechanisms contributing
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to a DCM cause, there are still unexplained causes [76]. In particular, the observed
phenotypes vary with respect to severity and prognosis.
The sequencing of the DCM samples was performed on IlluminaHiSeq instruments [11].
Per patient, roughly 2 billion bases have been sequenced. To ensure diagnostic quality
for clinical application, circa 99.1% of the targeted genomic region is covered at least
50-fold. In average, each patient carried 32 nsSNVs in the investigated target region.
In consequence, the coverage rate of our data set exceeds those used in classical exome
capture studies by several orders of magnitude [11].
Next, we collected available information concerning the data set nsSNVs deposited in
available databases [11]. To avoid bias, we collected information available from three dif-
ferent databases: SwissProt/UniProtKB (especially using the HUMSAVAR collection),
dbSNP including ClinVar and the HGMD. Further details about the used databases
can be found in Section 2.2. When information from more than one of the sources was
available (only 5% have information in all three databases), we built a majority-vote-
based consensus. While circa 60% are deposited in dbSNP with an rs ID, only 45%
have pathogenicity information available [11]. Figure 2.10 represents the detected pa-
thogenicity annotations in ClinVar, HUMSAVAR and the HGMD for the DCM data set.
Abbildung 2.10: Detected pathogenicity annotations [11].
The neutral labeled set and the disease-associated set comprise 192 and 147 nsSNVs,
respectively [11]. This annotated cardio test set, however, refers to only circa 45%
of our whole data set. A total of 55% of the nsSNVs in the DCM data set have no
available clinical significance information, and circa 40% have neither an rs ID nor other
known identifiers and annotations. This impressively demonstrates the lack of currently
available annotation concerning clinical information and phenotypic association of
genetic variants deposited in freely accessible databases.
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2.12.2 Control data from the 1000 Genomes Project
To be able to evaluate detected putatively DCM-related nsSNV patterns, Dr. Jan Haas
from the INHERITANCE Project Group generated a control set based on the general
population of the 1000 Genomes Project [73] (1000 genomes). The 1000 Genomes
Project sequences multiple genomes to provide a comprehensive resource on human
genetic variation.
Jan Haas downloaded the binary files (BAM) including the sequence data from 445
samples and applied the same variant calling and filtering algorithms, as described
for the analyzed DCM cohort [72]. In order to match the European INHERITANCE
cohort, we only considered individuals with a European descent: Utah residents with
northern and western European ancestry (CEU), Finnish in Finland (FIN), British in
England and Scotland (GBR), Iberian populations in Spain (IBS) and Toscani in Italy
(TSI) [73].
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The invent of Next-Generation Sequencing (NGS) techniques led to a substantial
amount of detected genetic variations, still rapidly growing. The vast amount of genetic
variant data consequently requires development of automatic procedures to predict the
functional and phenotypic effects of nsSNVs [11]. In the previous Chapter, Section 2.5,
we listed and briefly described state-of-the-art prediction tools to assess the pathogenic
influence of nsSNVs. Since in recent years, a number of approaches dealing with the
functional impact of genetic variants on protein function have been developed, the
choice of the best performing predictor has become difficult.
In consequence, evaluation studies have been performed to compare the available patho-
genicity prediction methods [11]. In 2010, Thusberg et al. analyzed the performance of
nine prediction tools on neutral (from dbSNP) and disease-associated (from PhenCode
database [77] and IDbases [78]) variant data sets [79]. Castellana and Mazza further
studied the uniformity of the predictions of six methods for whole-exome sequencing da-
ta [80]. Moreover, Frousios et al. evaluated the prediction performance of nine methods
on data from the HGMD and the 1000 Genomes Project, and developed a consensus
tool integrating four available prediction methods [81].
In this chapter, we describe and present the results of our study focusing on compre-
hensive evaluation of prediction concordance and prediction quality of existing tools as
well as discuss novel approaches to predict sets of nsSNVs. The following evaluation
study of pathogenicity prediction tools for single nsSNVs refers to already published
work [11] and constitutes the starting point for our analyses on nsSNV sets.
3.1 Concordance and performance of current state-of-the-art
pathogenicity prediction approaches
We systematically explored both, the concordance and performance of existing state-of-
the-art nsSNV pathogenicity prediction tools on panel sequencing results of 639 DCM
samples [11]. This NGS data set was screened for the full sequence of 76 genes, clinically
relevant for DCM and involves 842 nsSNVs. Due to the high coverage rate of at least
50-fold for 99.1% of the target region, the used DCM data set is of high clinical quality
(details see Section 2.12.1).
In contrast to previous studies, we extended the number of tested tools and applied
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these to the mentioned data set of high-quality. This study was already published in
[11]. Figure 3.1 outlines the underlying workflow.
In the following, we state the results most important for the presented thesis.
Abbildung 3.1: Graphical overview of the applied test workflow [11].
The selection of the 13 tested tools depended on characteristics important for the
majority of pathogenicity analyses: We only considered tools suitable for large-scale
studies without prerequisites that are not generally available, such as a homologous
3D structure or a dbSNP ID for prediction. Furthermore, we concentrated on tools,
frequently used in the scientific community.
For the calculations, the default parameters proposed and preset by each tool were
applied.
The statistical analysis of the 13 state-of-the-art pathogenicity prediction tools comprised
two components, the prediction congruency analysis and the prediction quality analysis.
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3.1.1 Concordance of prediction methods
Since no pathogenicity information for the complete data set is available, we first
focused on the analysis of congruency and association of the state-of-the-art methods.
In a first step, we calculated for all 842 nsSNVs in our data set the pathogenicity
prediction of the selected 13 tools. There are a dozen of computational tools aiming
at functional prediction of nsSNVs, thus, there are also approaches trying to build
an unified consensus classification score from them [82][83]. To avoid adding to the
complexity, we evaluated the straightfoward majority vote to build a consensus: for
each nsSNV, we determined the most frequent prediction result among the single
predicted ones. To evaluate the concordance, we computed for each single nsSNV a
consensus prediction out of all 13 prediction results and compared the consensus with
the prediction of each method, respectively. In addition to overall concordance, we
also analyzed the mutual concordance of the tested prediction tools. For each pair
of prediction methods, we calculated the similarity of their results concerning all 842
nsSNVs. The similarity score is defined as:
ScoreSimilarity =
∑
n∈nsSNV s
comparison(n) (3.1)
comparison(n) =
{
1 if prediction of Tool A and B for n are equal
−1 otherwise
(3.2)
We studied both, the overall concordance of one prediction tool compared to the con-
sensus of all prediction methods and the mutual agreement among all methods.
To evaluate the concordance of the 13 prediction methods, we determined the distribu-
tion of obtained prediction results on the complete data set of 842 nsSNVs (Section
3.2).
Although SIFT [84] and MutationAssessor [85] predicted about 50% of the 842 nsSNVs
to be disease-associated, the other methods proposed the majority of the nsSNVs to
be neutral. SNPs3D [86] (90%), PANTHER [33] (35%), MutationAssessor (29%), and
PolyPhen2 [35] (23%) failed to predict all of the 842 nsSNVs. In contrast, MutPred
[87], SNPs&GO [88], PhD-SNP [34], SNAP [89], PMut [90], PredictSNP [83] and
PROVEAN [37] had a prediction failure rate of less than 4%. Figure 3.3 illustrates the
comparison of each prediction tool to the consensus prediction result built using all
methods. PredictSNP, PROVEAN, PhD-SNP, SNPs&GO, and Condel achieved the
best conformity to the overall consensus.
Next, we created a network via Cytoscape [91] based on pairwise comparison of similarity
scores of the prediction results to evaluate the mutual agreement among the tested
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Abbildung 3.2: Distribution of obtained prediction results for the complete data set of
842 nsSNVs [11].
Abbildung 3.3: Comparison of single prediction with consensus prediction results for
the complete data set of 842 nsSNVs [11].
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Abbildung 3.4: Network of prediction concordance. Nodes represent prediction tools,
while edges mark the pairwise prediction similarity for connected nodes.
The dashed edges refer to a similarity of about 70− 80% and the bold
line edges to a similarity of > 80%. For clarity, edges with less similarity
value are neglected, except if one method includes another (pointed
edges). Pink arrow edges point to included tools. The color of the nodes
codes for concordance: purple = high, turquoise = moderate and blue
= low [11].
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methods (see Figure 3.4). For clarity, only edges marking at least 70% pairwise similarity
or connecting methods that incorporate other tools were recognized.
SNPs3D, PANTHER, MutationAssessor, and PolyPhen2 revealed the worst conformity
with all other tested tools. In contrast, PredictSNP, PROVEAN, MutPred, SNAP,
PMut, SNPs&GO, and PhD-SNP obtained the best concordance values with more than
80%. Except PROVEAN, these tools use machine learning classifiers for pathogenicity
prediction, and at least four include structural annotations.
Condel and PredictSNP build consensus predictions based on the single predictions
of other methods. Interestingly, machine learning-based applications cluster very well,
indicating the chosen classifier method to be essential for the prediction outcome (see
Figure 3.5). The underlying classification method even reveals greater influence on
the overall concordance than methods incorporating others. Moreover, tools including
others show not necessarily equal performance. These findings agree with previous
studies [79].
3.1.2 Performance of prediction methods
For 45% of the DCM data set, we were able to extract available pathogenicity annotations
from SwissProt/UniProtKB (HUMSAVAR collection), dbSNP including ClinVar and
the HGMD to create test sets for the performance evaluation of the selected prediction
tools. The neutral labeled set and the disease-associated set comprise 192 and 147
nsSNVs, respectively (details see Section 2.12.1).
In consequence, we were able to measure the prediction quality of the tested 13 prediction
tools on the generated test set of 339 annotated nsSNVs. We calculated the confusion
matrices [true positives (TP), true negatives (TN), false positives (FP), false negatives
(FN)] and consequently accuracy, specificity and sensitivity for the results of each single
prediction tool (detail see Section 2.9.1). We also computed the balanced accuracy
and the Matthews correlation coefficient (MCC) because the distribution of available
annotations concerning neutral and disease-associated nsSNVs is slightly imbalanced
(192 to 147).
The results of the prediction performance of the 13 tested tools in our study are shown
in Figure 3.6.
The best performance concerning balanced accuracy and sensitivity in combination
with prediction ability (NA ratio) was reached by MutPred with 66% accuracy, 96%
specificity, 28% sensitivity, 62% balanced accuracy and 0.32 MCC. Despite promising
balanced accuracy values, SNPs3D could classify only about 5% of our generated test
set. The remaining tools frequently showed a low hit ratio. In addition to SNPs3D and
MutationAssessor, most methods revealed much higher specificity values compared to
sensitivity. The mean values for accuracy (60%), specificity (69%), sensitivity (49%),
balanced accuracy (59%) and MCC (0.20) show the current limitations of nsSNV
pathogenicity prediction.
Furthermore, we determined the performance quality of the consensus prediction result,
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Abbildung 3.5: Heatmap of the prediction results obtained by the 13 state-of-the-art
prediction tools. Tools based on machine learning cluster well, indicating
that the chosen classifier method is essential for the prediction outcome
[11].
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Abbildung 3.6: Prediction results of the 13 tested state-of-the-art tools on 339 nsSNVs
with available pathogenicity annotations [11].
computed for each nsSNV during congruency analysis. Cases with balanced 50% vote
were excluded within calculation of prediction measures. Referring to the methods’
close correlations, we also clustered related methods to build a consensus prediction
of non-overlapping tools and calculated a kind of nested majority vote. First, we
determined the majority vote for related methods. Next, we determined the majority
vote over all these sub-majority votes. In particular, we compared structure-based and
sequence-based methods to try to improve the prediction results. We discriminated
between the structure-based group (MutPred, PMut, SNAP, SNPs3D, PolyPhen2)
and the sequence-based group (PROVEAN, SNPs&GO, SIFT, PANTHER, PhD-SNP,
MutationAssessor). We also clustered related methods, namely methods using the same
classification method or prediction features: machine learning-based group (MutPred,
SNPs&GO, SNPs3D, PhD-SNP, SNAP, PMut) and the non machine learning-based
group (PANTHER, PROVEAN, Condel, PolyPhen2, SIFT, MutationAssessor). Since
PredictSNP builds a consensus of sequence- and structure-based methods as well as
incorporates machine learning and non machine learning-based tools, we excluded this
method from our consensus calculation. The resulting quality measures are presented
in Table 3.1.
The consensus predictions of machine learning (ML) and structure information-including
methods reveal slightly improved accuracy values. We also built a consensus of the
results obtained by structure-based and sequence-based methods, which yielded the best
consensus prediction result with 65% accuracy (balanced accuracy 63%) and about 63%
sensitivity. In addition, the sequence structure consensus as well as the ML consensus
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Tabelle 3.1: Prediction results of clustered prediction methods. Sequence consensus: consensus predicti-
on of sequence-based group; structure-consensus: consensus prediction of structure-based
group; sequence structure consensus: consensus prediction from sequence and structure
consensus; Machine Learning (ML) consensus: consensus prediction of related methods
divided into the machine learning group and the non-machine learning group [11].
Accuracy Specificity Sensitivity Balanced
accuracy
MCC NA
Sequence con-
sensus
57.7 63.44 50.34 56.89 0.14 2.4
Structure con-
sensus
62.73 76.24 45.39 60.82 0.23 5.0
Sequence
structure
consensus
65.0 66.0 62.86 64.43 0.27 0
ML consensus 63.74 64.43 61.76 63.1 0.24 0
were able to return a result for each nsSNV in the data set.
3.1.3 Discussion
We analyzed the concordance and performance of current state-of-the-art pathogenicity
prediction tools to identify the best method to prioritize nsSNVs as disease cause. Du-
ring our extensive analysis, we identified several critical drawbacks within the current
state-of-the-art pathogenicity prediction strategies.
Many existing prediction methods are not well suited for large-scale studies with real-life
data. Often only server-based applications are available, and/or the input is restricted
to single sequence variants in one query.
In addition, a major problem concerning all computational methods and databases
is the maintenance of the developed software. Rare updates lead to obsolete anno-
tation linkages and can even negatively influence classification results. In fact, some
of the available supposedly neutral nsSNV data sets used in former studies contain
disease-associated mutations according to actual database entries. We identified, for
example, some variants in the neutral VariBench data set of Thusberg et al. [79], as
disease-associated, with entries in the HGMD [6]. The major problem in general refers
to the limited availability of suitable data and, particularly, high-quality data. Often
data sets are constructed from information contained in one particular database without
cross-checking these information in additional databases. Some information missing in
one database might be available in another. Sometimes, even annotations from different
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data sources disagree. In particular, the construction of a neutral labeled data set
is highly challenging. Hence, we constructed our positive and negative data sets as
consensus out of the three most popular databases for nsSNVs. Based on our findings,
we recommend using a consensus of different available data sources to avoid biased
data sets in future studies.
The choice of the data and the data quality play an essential role in performance and
evaluation studies. Especially the data quality in former studies often varies: Frousios et
al., for example, based their analysis partly on low-coverage whole-genome sequencing
data [81]. In contrast, our analysis focuses mainly on high-coverage data for targeted
sequencing with 99.1% of the targeted genomic region covered at least 50-fold.
Furthermore, none of the currently available approaches consider neighboring nsSNVs
or the influence of several nsSNVs. A human individual usually carries more than one
nsSNV, and from a medical point of view, especially, the individual combination of
nsSNVs plays a crucial role in clinical diagnostics concerning e.g. personalized medicine.
3.1.4 Familial study on glioblastoma multiforme (GBM)
In a familial exome sequencing study of unaffected parents and their two siblings
diagnosed with glioblastoma multiforme (GBM), we were able to identify genes with
accumulations of homozygous and heterozygous germline variants within both siblings
[92]. GBM is the most aggressive and malignant subtype of human brain tumors. The
identified accumulations of homozygous and heterozygous variants could not be detected
in the healthy parents and thus, might contribute additively to the siblings’ observed
phenotype. Figure 3.7 exemplarily illustrates the encoded protein structure of Chitinase-
3-like protein 1 (CHI3L1 ), one of the detected genes with variant accumulations.
CHI3L1 plays an important role in the regulation of malignant transformation and local
invasiveness in gliomas, since it is highly expressed in human glioma tissue. Within our
samples of the two siblings, CHI3L1 revealed several homozygous and heterozygous
mutations not present in the parents’ exome.
Unfortunately, computational methods to analyze putative synergetic effects of multiple
variants in one gene on the cause and severity of a disease are currently missing. In
consequence, we aimed to improve this unsatisfactory situation by developing novel
strategies to promote the assessment of nsSNV sets in one gene and its coding protein.
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Abbildung 3.7: 3D structure of chitinase-3-like protein 1 (CHI3L1 ) [92]. The four chains
of CHI3L1 are colored according to their secondary structure elements.
To highlight the distribution of the detected mutations within one chain,
chain C is colored in grey. We distinct between homozygous (pink) and
heterozygous (orange) mutations.
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3.2 From single nsSNV prediction to the assessment of
nsSNV sets
The major drawback of probably all currently available pathogenicity prediction tools
is their restriction to one single nsSNV per gene or one single mutation per protein,
respectively. This ’one-SNV, one-phenotype’-paradigm, however, is not able to cover
the whole range of nsSNV impact on a protein’s function regarding diseases such as
diabetes or GBM [8]. The computational features suitable for the detection of putative
synergetic effects of several nsSNVs in one gene, though, are limited.
In order to develop an approach to assess the effect of multiple nsSNVs, we first tried to
detect mutation patterns specific for disease enabling the formulation of classification
rules for the pathogenicity prediction of nsSNV sets on the example of the DCM data
set of 639 samples (see 2.12.1). To this end, we analyzed amino acid distributions at
wild type and mutant positions as well as patterns of amino acid substitutions specific
for DCM-linked nsSNVs for the 339 annotated nsSNVs within the DCM samples.
Next, we tried to implement computational scores discriminating between disease-
associated and neutral nsSNV sets by adaption of strategies used for the pathogenicity
prediction of single nsSNVs. In particular, we focused on features available for the
majority of NGS data, such as e.g. the protein sequence, instead of 3D structure
information, which is unfortunately often missing.
In the following, we refer to the wild type (WT) amino acid as the unmutated position
in the reference genome and the mutant (MT) amino acid as the position in the patient
data differing from the reference genome.
3.2.1 Analysis of amino acid distributions in DCM samples
Since we have been able to create a test set of neutral (192) and disease-associated
(147) nsSNVs within the DCM data based on annotations in SwissProt/UniProtKB
(HUMSAVAR collection), dbSNP including ClinVar and the HGMD, we calculated the
amino acid distribution in the neutral and disease labeled DCM test set (see Section
2.12.1) as well as frequencies for WT and MT residues. In particular, we compared the
observed frequencies with the expected values determined based on the distribution
of all amino acids in the test set. The expected values are also computed with regard
to codon diversity and the probability to generate a certain substitution referring to
all possibilities for a translation from a specific amino acid to another by only one
triplet base mutation of the WT codon. The applied formulas for expected and observed
frequencies are defined in Section 2.9.2.
To compare WT and MT residues within substitutions, we computed a BLOSUM62
matrix-based dissimilarity score [93], defined as:
Scorediss = |BLOSUM62(WT aa,MT aa)−BLOSUM62(WT aa,WT aa)|
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where aa abbreviates amino acid.
Since the identity of BLOSUM62 equals the maximum value and less similar substi-
tutions tend to receive negative values, the higher the score the less similar are the
substituted amino acids.
In general, the resulting amino acid distributions at WT and MT residues are quite
similar (see Figure 3.8). Except at MT positions in the disease-labeled DCM data,
arginine (R) is observed most often, even more frequently as expected (Figure 3.8, part
C). R, together with serine (S) and leucine (L), refers to the three amino acids with
the most coding triplets (6). Moreover, R was detected as the most frequently mutated
WT residue in the considered data set, however, it also reveals the highest occurrence
within the analyzed DCM data. Hence, the probability to mutate one of the R residues
compared to others is higher.
In contrast to the neutral-labeled DCM set, methionine (M) and tryptophan (W)
reveal higher observed frequencies in the disease-annotated DCM data as expected
(Figure 3.8, part D). Interestingly, M and W are encoded by only one single codon,
and thus, the probability to obtain a M or W residue by one single base mutation
is lower compared to the rest of the standard amino acids. Khan et al. analyzed the
mutational spectrum of amino acids within protein secondary structure elements such
as helices, beta strands and turns. According to their study, M is the only significant
MT residue concerning alpha helices [41]. Together with cysteine (C), M is one of two
sulfur-containing amino acids. Its thiol side chain also reveals high reactivity [21]. W is
the less most occuring amino acid among the 20 standard amino acids. Characteristic
for W is its bicyclic structure, consisting of a six-membered benzene ring fused to a
five-membered nitrogen-containing pyrrole ring [21]. A substitution resulting in an
inserted M or W residue may alter binding affinities within a protein because of the
higher reactivity of M or introduce steric clashes due to the size of W modifying a
protein’s folding. These effects may promote disease-associated dysfunctions of proteins.
Furthermore, we investigated the relationship of mutations correlated with their physico-
chemical properties. To this end, we distinguished five groups: non-polar (G, A, V, L,
M, I), polar (S, T, C, P, N, Q), aromatic (F, Y, W), positively charged (K, R, H) and
negatively charged (D, E) amino acids. Explanations for the amino acid abbreviations
can be found in 6.1. The results are illustrated in Figure 3.9. In general, non-polar
residues represent the majority of WT and MT residues, respectively. Besides these,
aromatic amino acids are most frequently detected at neutral-annotated MT positions
of the DCM set. In contrast, the majority of disease-associated MT positions in the
DCM data is composed of positive-charged residues.
Beyond the single amino acid distributions, we also studied whether the spectrum
of combination of WT and MT residues reveals substitutions specific for disease or
neutral-annotated DCM data. Based on all MT residues, which can result from the
observed WT by one base change within its triplet, we determined the most frequent
mutations and calculated the probability to generate certain substitutions (formula
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Abbildung 3.8: Distribution of amino acids at WT (wt) and MT (mt) residues in
neutral and disease set of the DCM samples. The axes are labeled
by the calculated expected versus the observed occurence of the WT
and MT residues, respectively. “Neutral info wt obs” e.g. refers to
the observed WT occurence within the neutral labeled data set, while
“disease info mt exp” denotes the expected occurence of the MT residue
within the disease-associated data, and so on.
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Abbildung 3.9: Distribution of amino acids with certain physico-chemical properties at
WT and MT residue positions. The red-colored lines denote the results
for disease-labeled DCM data, while the gray printed lines refer to the
neutral-annotated DCM set.
definitions see Section 2.9.2). To study WT and MT residues within substitutions, we
computed a BLOSUM62 based similarity score as described above. The obtained results
are displayed in Figure 3.10. Substitutions with low similarity of the involved WT and
MT amino acids in combination with the highest frequency values are R-C, P-L, R-W,
G-R, T-M, G-S, and T-I. Interestingly, only P-L and G-R among these substitutions
have with 16% and 25% the highest probability values based on codon diversity for a
transition from the WT to the detected MT residue by on base change within the WT
triplet. In the remaining cases with probability values from 1.2% to 8.3%, a subsitution
to a different MT residue would have been more probable according to the genetic code.
In general, no distinct differences in the amino acid substitutions could be determined
between the disease and neutral-labeled data sets according to observed and expected
frequencies, respectively. Except the substitution T-M could be observed noticeably
more often than expected in the disease-annotated data. This at least agrees with the
findings of single amino acid distributions, since a substitution to M reveals higher
observed frequencies in the disease-annotated DCM data as expected.
The definition of putative mutation rules specific for pathogenic relation of nsSNVs
based on the identified amino acid substitution patterns, however, was not possible.
The observed results did not allow a distinct classification of amino acid substitutions
in DCM patient samples into pathogenic or benign. The identified difference of amino
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Abbildung 3.10: Amino acid substitution frequencies in both, neutral and
disease data set.
48
3 Current pathogenicity prediction of nsSNVs - benefits and drawbacks
acid substitutions between these two groups are only marginal and thus, not significant
enough for a classification. Unfortunately, we were not able to determine an exceeding
subsitution pattern in one of the analyzed sets in the DCM cohort.
In fact, the distribution of the amino acid substitutions and the substitution pairs in
both, disease and neutral-labeled DCM samples are presumably not the major cause for
a detectable, functional impact and do not provide the capability to promote nsSNV
assessment.
Next, we tried to adapt existing features for single nsSNV prediction to computationally
predict the effect of nsSNV sets.
3.2.2 Definition of pathogenicity prediction scores for nsSNV sets
To measure the effect of nsSNV sets including putative additive effects and consequently
establish a prediction strategy, we require sophisticated scoring functions. Based on
systematic studies of applied scoring methods in single SNV prediction, we developed
the following measures:
• BLOSUM Score
• PSSM Score
• Secondary Structure Score
All defined scoring methods compare WT and MT sequence, while the MT sequence
includes all amino acid substitutions within a protein detected in one patient sample.
In the following, we first present the detailed score definitions and then, we describe
the corresponding performance tests and the analysis of the obtained results.
BLOSUM Score
Some of the established approaches for single SNV prediction are homology-based
methods and thus, perform nsSNV classification into disease-associated or benign
via substitution matrices such as BLOSUM62 to judge the similarity of amino acid
substitutions in interchanges between homologous proteins [93] (details in Section
2.9.3).
The formulated BLOSUM Score computes the similarity of WT and MT sequence using
the BLOSUM62 substitution matrix:
ScoreBLOSUM = 1−
|
∑
AAwt∈seqwt
BLOSUM62[AAwt]−
∑
AAmt∈seqmt
BLOSUM62[AAmt] |
length(seqwt)
(3.3)
49
3.2 From single nsSNV prediction to the assessment of nsSNV sets
where AA refers to amino acid, wt codes for WT and mt for MT.
Since identical amino acids receive maximum values in the BLOSUM62 matrix, low
ScoreBLOSUM -values indicate the substitution of amino acids with completely different
properties and hence, may alter protein stability and/or function. A detailed threshold
for discrimination of disease and neutral mutations, however, requires systematic tests
on high-quality data (see Section 3.2.3).
PSSM Score
Amino acid residues that have been conserved within a protein family more likely
play an important role in protein function compared to unconserved ones, since they
frequently encode for functional important sites of the protein [94]. To translate the
evolutionary information profiles of single mutations to multiple substitutions, we built
a conservation-based PSSM score to compare WT and MT protein sequence.
We used the position-specific scoring matrix (PSSM) to create an evolutionary profile
score for the mutated amino acid positions (Section 2.9.5). The PSSM takes into account
which residues are observed at each position in a sequence alignment of evolutionary
related sequences [44]. It measures the amino acid substitution frequencies amongst
protein families identified and curated in databases. In consequence, the developed
PSSM Score describes the degree of conversation of substituted positions and the
evolutionary occurrence of the introduced amino acids at these positions (Section 2.9.5).
Amino acid substitutions, which do not comply with the substitution profile of a protein
family, indicate destructive influence on the corresponding protein and consequently
may contribute to the cause or severity of a disease.
The PSSM score is defined as:
ScorePSSM =
∑
#AA
PSSM [AAwt]− PSSM [AAmt]
length(seqwt)
, (3.4)
where ’#’ refers to ’number of’, AA refers to amino acid, wt codes for WT and mt for
MT. For the calculation of the PSSM matrices for WT and MT sequences, we applied
the available software tool PSI-BLAST from the BLAST package version 2.2.28 (see
Section 2.9.4).
Secondary Structure Score
Structural information is essential when discriminating nsSNVs affecting protein functi-
on from functionally neutral ones [11]. Since the arrangement of structural building
blocks plays an important role in specific protein folding and hence, modifications may
have a tremendous effect on protein stability and function, we compared the sequence
of secondary structure elements of WT and MT protein sequences.
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The determination of the secondary structure based on sequence information alone is by
now highly accurate using efficient computational methods such as the state-of-the-art
tool PSIPRED [46]. In consequence, we used the PSIPRED tool version 3.3 (see Section
2.9.6) to perform secondary structure prediction and on the basis of these results as
well as the properties of secondary structure elements, we developed the Secondary
Structure Score (ScoreSecStruct), defined as:
ScoreSecStruct = 1− #mismatches
length(seqwt)
, (3.5)
where ’#’ refers to ’number of’, wt codes for WT and a mismatch is valid if at least
the two preceding positions in the alignment of WT and MT secondary structure also
differ.
Figure 3.11 illustrates a simple example.
Abbildung 3.11: Example for the defined secondary structure score. The secondary
structure elements are denoted as: C = coil, H = helix and E = sheet.
A shift by one position may occur due to the prediction method. In
particular, we defined three consecutive mismatches as lower boundary
for a modified secondary structure sequence.
A shift by one position within the secondary structure may occur due to the prediction
method. Moreover, a helical turn comprises approximately four amino acids and the
disruption of a helix is supposed to critically influence protein stability [95]. Therefore
we account for mismatches only cases where three consecutive alignment positions
differ.
In fact, we were able to detect modifications in the secondary structure introduced by
amino acid substitutions. Interestingly, these changes not necessarily occurred exactly
at the substituted position or close to it indicating a potential influence of tertiary
interactions on the mutational impact.
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3.2.3 Analysis of the defined prediction scores for nsSNV sets
To test whether the designed scores are suitable to capture putative synergetic effects
of nsSNV sets, we selected 58 test samples including 8 genes from the DCM data set
(Section 2.12.1). These samples denote different nsSNV sets in one gene detected in
DCM patients. Furthermore, the selected test samples comprise minimal overlaps of
one or two nsSNVs within one gene. Due to these overlaps, we were also able to analyze
the influence of a particular nsSNV in combination of several others. An example for 3
selected test samples refers to:
Gene Symbol Transcript nsSNV sets
ADRB1 NM 000684 S49G, G389R, V5A
ADRB1 NM 000684 S49G, G389R
ADRB1 NM 000684 A187V, G389R
The small size of the data set and the selected samples allowed for a precise analysis of
the characteristics and strengths of each defined score in two aspects: the comparison
of the scores to each other as well as with respect to the detection capability of accu-
mulation effects.
Referring to this small test set, we calculated ScoreBLOSUM , ScorePSSM and
ScoreSecStruct values for the overlapping nsSNV sets. Unfortunately, we were not
able to detect significant differences between the related nsSNV sets. Though the most
promising of the scores refers to the Secondary Structure Score, its validation requires
extensive studies to analyze which modifications of the secondary building blocks in
fact have an impact on protein folding and function.
The validation of the calculated scores, however, emerged to be more difficult than
anticipated. To the best of our knowledge, currently no data on nsSNV sets and their
corresponding functional impact exist, and thus, neither reference scores nor scores for
comparisons enabling a threshold definition are available. The assessment whether a
certain value of a specific score indicates disease association or functional neutrality
without control data proved elusive.
We computed ScoreBLOSUM , ScorePSSM and ScoreSecStruct for all 339 annotated nsS-
NVs from the DCM data set (Section 2.12.1) to define thresholds to distinct between
disease and neutral predicting scores. Based on the available pathogenicity annotations
for the 339 nsSNVs, we were able to rank the nsSNVs due to their calculated scores and
compare the distribution of neutral and disease annotated nsSNVs among the top scored
results, respectively. Unfortunately, besides disease-associated nsSNVs also neutral-
labeled mutations obtained worse scoring results. In addition, Wilcoxon-Mann-Withney
tests on the neutral and disease distribution of the nsSNVs and their corresponding
calculated scores revealed no statistically significant difference between both test sets
for all three scores.
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3.3 Conclusion
The comprehensive analysis of evaluation and prediction performance of 13 existing
tools, which aim to predict the functional impact of nsSNVs (see Section 3.1), revealed
major drawbacks concerning current state-of-the-art pathogenicity prediction.
The prediction of single nsSNVs is not able to substantially promote the improvement
of computational diagnostics, since common diseases such as diabetes and cancer are
caused and influenced by a varying number of genetic variants [96]. In particular,
previous studies revealed variants involved in common diseases do not occur at highly
conserved regions, however, current prediction methods often rely on conserved features
and hence, fail to assess their pathogenic influence [97].
In a familial study of healthy parents and their GBM diagnosed children, we could
identify variant accumulations detected in specific genes of the children but not present
in their parents [92]. Single variants revealed no pathogenic phenotype in the parents,
but their accumulations in the childrens’ genome might have additively contributed to
their observed disease. Computational methods to predict the disease association of
nsSNV sets or to analyze putative synergetic effects of several nsSNVs within one gene,
however, are currently missing.
In a simple approach, we tried to adapt existing measures to capture the functional
influence of single nsSNVs to the prediction of nsSNV sets. At present, the effects
triggering synergetic events introduced by nsSNV sets have not been deciphered so
far, and therefore, a definition of computational features for these events is highly
challenging. Furthermore, their validation is laborious and time-consuming or even
not possible. Our analysis, however, suggests the limitations of current state-of-the-art
prediction features for single nsSNV assessment to be adapted in prediction approaches
for multiple nsSNVs.
In particular, the presented studies on congruency and performance of available pa-
thogenicity prediction tools as well as the trial to adapt their prediction strategies
for multiple nsSNVs, revealed the importance of 3D structure information within the
process of detecting pathogenic nsSNVs. Though this information is often limited,
approaches to predict the functional impact of nsSNVs are proposed to include these
whenever possible. Furthermore, our analysis with respect to the secondary structure
score indicates a crucial influence of tertiary interactions, since the mutational effect
of nsSNVs not necessarily resides local at substituted positions within a 3D structure.
A putative synergetic effect of nsSNV sets underlies complex correlations and the
identification of these requires the integration of available information - regardless if
genetic or structural - within computational assessment.
Moreover, to improve clinical treatment, developed approaches have to be designed
to meet the requirements on clinical application. Experience has demonstrated the
importance of imaging techniques in clinics, such as e.g. magnetic resonance tomography.
Visual inspection of the effect introduced by several amino acid substitutions within
a 3D protein structure might reveal crucial insights in the mechanisms promoting
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dysfunction.
In conclusion, we consequently combined genetic and structural information to imple-
ment a software tool - BALL-SNP - to identify candidate nsSNVs for computational
diagnostics. BALL-SNP is presented in detail in the next chapter.
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The experimental analysis of the growing amount of detected genetic variations in NGS
studies is too cost- and time intensive, while current in silico nsSNV pathogenicity
prediction tools are not able to contribute to the improvement of clinical and treatment
prognoses.
To identify candidate nsSNVs and hence, to promote the application of NGS in
clinics, we developed the software tool BALL-SNP, freely available at http://www.
ccb.uni-saarland.de/BALL-SNP [98]. BALL-SNP serves as a new pipeline for the
assessment of multiple nsSNVs in NGS data. It is based on the Biochemical Algorithms
Library (BALL) [47] and integrated in BALL’s visualization front-end BALLView
[50]. BALL is a comprehensive application framework for rapid software prototyping,
which offers a large number of molecular data structures and algorithms allowing for
sophisticated development of new approaches [98]. Details about the framework are
summarized in Section 2.10.1.
Since we aim to combine genetic and structural information, while ensuring intuitive
usability, we take advantage of BALL’s rich functionality. We extended the versatile
C++ class library by adding functionality to import and process Variant Call Format
(VCF) based file formats used in DNA sequencing, SNP calling and SNP annotation. We
furthermore embedded the currently most important SNV annotation databases (see
Section 2.2) and corresponding parsing methods [98]. Since synergetic effects of several
mutations aggregating in a protein structure may additively contribute to an observed
dysfunction, we implemented a hierarchical bottom-up clustering for mutated residues.
In addition, we introduced a compute server and the associated request/response
functionality allowing for straightforward integration of available prediction tools [98].
Figure 4.1 outlines the BALL-SNP workflow along with all incorporated data sources.
Besides the 3D visualization, we display additional generated information in an acces-
sible HTML-based interface, facilitating a clearly arranged presentation [98]. Moreo-
ver, as BALL-SNP is implemented on top of the standard molecular modelling tool
BALLView, an intuitive and direct interaction of the user with the visualized 3D
structure representations is possible.
In the following, we point out the main functionality extensions and give an overview
about the implementation details developed within this thesis.
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Abbildung 4.1: General BALL-SNP workflow (adapted from [98]).
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4.1 Design and Implementation
The BALL implementation is structured into BALL core functionality and classes
responsible for the visualization front-end BALLView, the VIEW component. A major
part of the VIEW implementation refers to Qt derived classes creating and handling
widgets, dialogs and so on.
The required extensions for BALL-SNP reside in both, the core of BALL and the VIEW
component. Figure 4.2 gives an overview of the implemented classes and functionality
necessary for BALL-SNP.
Here, we briefly summarize the implemented C++ classes and their tasks within BALL-
SNP.
SNPFile incorporates all attributes and member functions necessary to read and process
the content of the allowed input format files (see Section 2.10.2). The SNPFileDialog
refers to a central class offering access to diverse functionality. Since we focus on the
development of a tool, which is easy to use, in particular to non-experts of molecular
modelling or further specialized software, such a class delegating the analysis pipeline
without extensive user interaction was necessary. The SNPFileDialog connects and
triggers certain instances to generate SNV specific information from e.g. annotation
databases, available prediction tools and from structural features (see workflow Figure
4.1).
We also constructed a compute server to allow out-sourced, cost-intensive calcula-
tions, such as for example SNV pathogenicity predictions. The interface classes to
communicate with the constructed compute server refer to DownloadModelFile and
DownloadPredictions. Both include QtNetwork functionality with QtNetworkReply
and QtNetworkAccessManager to process server requests and the corresponding server
responses.
Since experimentally gained knowledge about nsSNVs is curated in freely available
databases (Section 2.2), we implemented a class to parse and make use of these available
information, the DatabaseParser class.
Structural features such amino acid substitutions aggregating within subunits of a
protein can shed light on the mechanisms steering dysfunction. Hence, we introduced me-
thods to analyze the spatial relations of amino acid substitutions. The SNPClustering
class conducts SNV cluster analysis and stores required cluster properties in instances
of the SNPCluster class.
The DatabaseInterface class is responsible for the representation of the informa-
tion content prepared and generated by, for example, the DatabaseParser and the
SNPClustering, as well as for the intuitive visualization of these information on an
information page widget.
Besides, further add-ons had been necessary for e.g. notification purposes, and were
not specific for a certain functionality than rather crucial for all made extensions.
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Abbildung 4.2: UML diagram of the implemented extensions and the most important
components in BALL-SNP. Purple-colored classes refer to the BALL
core, while turquois ones belong to the VIEW component. The blue
dash-lined classes specify the interface to the constructed compute
server.
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BALL handles communication of all widgets and dialogs in the GUI of BALLView
through message posting to inform about modifications in a running BALLView instance.
To integrate also SNV-relevant messages and their handling, we added a new message
type called SNPdataMessage to inform notifying components about LOAD, RESET
and CLUSTER events concerning SNV data.
Since we generate a large amount of information, we introduced new coloring schemes
to enable information-based coloring of the 3D content:
• COLORING PATHOGENICITY: colors mutated residues according to their available
pathogenicity information
• COLORING INTERACTION: labels mutated residues with available interaction site
information
• COLORING CLUSTER: highlights mutated residues based on the determined cluster
affiliation
A molecular structure is partitioned into subcomponents such as e.g. atoms, residues
and proteins. To be able to create representations colored according to specific nsSNV
characteristics, we added new properties in the existing residue class to assign these:
• PROPERTY MUTATED: labels a mutated residue
• PROPERTY PATHOGENIC: assigned to a residue with pathogenic information
• PROPERTY BENIGN: assigned to a residue with benign information
• PROPERTY WITH INTERACTION: tags a residue with available interaction site infor-
mation
Furthermore, the additional attribute cluster id to maintain the cluster affiliation
and thus, enable the ad hoc selection of cluster distance thresholds, was required.
For the database parsing functionality, we included several python scripts in BALL-
SNP to preprocess the different formats of the available data sources and to enable a
straightforward update of these without intricately modifying C++ code.
In the following, we describe the functionality of the implemented classes in detail.
4.2 Adjustment of PDB residue information
BALL-SNP critically depends on 3D structures and is consequently connected to the
Protein Data Bank (PDB), the most comprehensive archive for 3D structural data
of biological macromolecules world-wide [27] (see Section 2.3 for details). Since the
standard BALL-SNP input file does neither contain any information about encoded
proteins nor information on available 3D content, we parse the required information from
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the UniProtKB, which also links available PDB ids. Unfortunately, the PDB information
concerning length as well as start and end indices deposited in the UniProtKB are
partially inconsistent with the correct information within the PDB file. Moreover,
one protein entry may have several PDB identifiers listed in the UniProtKB. To
automatically identify the largest structure with the best quality available, we first
adjusted the PDB residue information in the UniProtKB and then, compared length
and quality of each listed PDB structure. The index adjustment was performed by
pairwise alignments of the UniProtKB FASTA sequence (see Section 2.7) and the PDB
file ATOM entries within a PDB, since the FASTA sequence within the header of a
PDB file not necessarily matches the actual structure sequence of the protein given by
the ATOM entries in the PDB file (see Section 2.8 for more details). A Python script
preprocesses the parsed UniProtKB in the described form and returns a file mapping
UniProtKB identifier to the best available 3D structure in the PDB to allow fast access
and direct use in BALL-SNP.
Besides the index information deposited in the UniProtKB, the range of the residue
indices within the ATOM records of a PDB file additionally not necessarily corresponds
to the actual sequence indices. Since we have retrieved the correct residue indices during
the correction of the UniProtKB information, we are able to check whether the residue
index within the PDB file is correct or not and adjust it if necessary. The adjustment
is performed when the PDB file has been automatically downloaded by BALL-SNP
and a visualization is created.
4.3 3D modelling information to overcome missing PDB
information
Unfortunately, the gap between known protein sequences and available 3D protein
structures is still huge. Since BALL-SNP, however, relies on the 3D information of a
protein, we added the possibility to automatically search for templates in ModBase, a
well-established database of comparative protein structure models (details in Section
2.10.4).
Therefore, we setup a compute server including the required request and response
functionality. The request is created based on the UniProtKB identifier and a list of
introduced amino acid substitutions, where a substitution refers to wild type amino
acid + protein residue position + mutant amino acid, e.g. G65S for glycine is mutated
at position 65 to a serine. The built compute server is assigned different functionality
purposes of BALL-SNP and hence, the 3D model search pipeline requires the flag
“MODEL” to specify which implemented pipeline to trigger. The request syntax using
standard HTTP query strings matches:
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http://www.ccb.uni-saarland.de/ballsnp/cgi-bin/index.py?
seq= MODEL
&uid= UniProtKB id
&mut= mutation list separated with ‘‘ ’’
The python pipeline called by the constructed compute-server in BALL-SNP to auto-
matically search for a 3D model basically consists of the following steps:
• search ModBase file for the best available 3D model for the given UniProtKB
identifier
• check if at least one of the provided amino acid substitutions is comprised in the
selected 3D model
• download the coordinate file (PDB) for the identified best 3D model of the given
UniProtKB identifier from ModBase server
The quality of the available 3D models is scored based on sequence identity, e-value and
DOPE score. We only consider models with more than 60% sequence identity and low
values for e-value and DOPE score. These specifications refer to standard parameters
used in molecular modelling. The resulting 3D structure of the target sequence is
returned to the compute server and BALL-SNP, respectively.
4.4 Integration of available approaches on nsSNV assessment
In recent years, software tools to predict the impact of single nsSNVs on a protein’s
structure and function have been developed. Details about current state-of-the-art pre-
diction tools are outlined in Section 2.5. Since often experimentally gained information
deposited in databases is not available, we selected promising methods for integration
into BALL-SNP to make use of their functionality.
To be independent of the software maintenance by a third party and to guarantee stable
performance, we currently only focus on the integration of available stand-alone software
tools [98]. The underlying databases and resources of all these available approaches,
however, exceed the portable size of a downloadable, freely available software tool with
a comprehensive molecular modelling library, such as BALL-SNP. Furthermore, the
required input formats as well as the obtained output are often incompatible among the
tools and thus, a combination of different prediction tools requires additional analysis. In
consequence, a straightforward integration was achieved by out-sourcing the calculation
of source-expensive approaches on a compute server.
4.4.1 The compute server functionality
As already mentioned, we setup a compute server for the 3D model search in ModBase
when no 3D information is available in the PDB. This compute server was extended to
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conduct the prediction of pathogenicity and protein stability changes, respectively. The
stand-alone versions of the selected methods were installed on the created compute
server and accessed by an implemented server script. This script decides based on
specified flags (e.g. “MODEL”, see Section 4.3) which pipeline to trigger.
BALL-SNP offers the possibility to send a request to this server and to process the
corresponding response, accordingly. The BALL-SNP compute server interface corre-
sponds to the implemented classes DownloadModelFile and DownloadPredictions,
illustrated in Figure 4.2.
A general server request based on standard HTTP query strings currently refers to:
http://www.ccb.uni-saarland.de/ballsnp/cgi-bin/index.py?
seq= FASTA sequence
&uid= UniProtKB id
&mut= mutation list separated with ‘‘ ’’
where the seq parameter serves as flag in the 3D model construction pipeline (Section
4.3).
BALL-SNP waits and locks the remaining processes until it receives the response to
the made request. Since the computation time increases with the number of nsSNVs in
the input file, users can decide whether to generate and include this information or just
focus on the remaining information [98].
The subsections below elaborate on the integrated functionality.
4.4.2 Protein stability change
Proteins properly folded have minimal potential energy and are usually stable [98].
Amino acid substitutions introducing a change in the protein sequence can have a
significant impact on the potential energy of the protein structure, and thus its folding
and stability. Consequently, the analysis to which extent a mutation affects protein
stability with respect to the wild type, extends the understanding of the mutation
impact on protein function and the genotype-phenotype relationship, accordingly [98].
Several methods to predict the change of a protein’s binding free energy exist [12][99].
Among these, I-Mutant was shown to have better performance compared to the other
available tools [100]. The implemented compute server runs the freely accessible I-
Mutant 2.0 code. I-Mutant 2.0 [38] uses SVMs to automatically predict protein stability
changes caused by single point mutations in protein sequence (Section 2.6).
4.4.3 Pathogenicity prediction
Since the experimental analysis to gain knowledge concerning the pathogenicity of
nsSNVs is laborious and time-consuming, computational approaches have been de-
veloped to predict the impact of an amino acid substitution on protein function in
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silico. In Section 2.5, we list the available prediction tools integrated in BALL-SNP:
PANTHER [32], PhD-SNP [34], PolyPhen2 [35] and PROVEAN [37]. The tool selection
depended on stand-alone functionality and prediction strategy. We aimed to cover a
broad range of different strategies to assess the pathogenic effect of an nsSNV. Beyond
sequence-related features, structural features to analyze the genotype - phenotype
relationship are essential (PolyPhen2).
Additional to the PROVEAN prediction tool, we include precomputed PROVEAN
scores available at http://provean.jcvi.org, because PROVEAN emerged to be
generally too time-consuming for an interactive workflow in BALL-SNP (see Section
2.5.4).
In a recent study, we were able to show, that prediction accuracy and sensitivity can be
further improved by calculating a consensus score for each single nsSNV [11]. Hence, we
define an intuitive majority-based consensus score built on the single prediction results:
Scorem =
∑
t∈tools
Pt
{
1 if Pt = neutral
−1 if Pt = disease (4.1)
where Pt refers to the prediction result of tool t.
consensus =

neutral if Scorem > 0
disease if Scorem < 0
none otherwise
(4.2)
The majority-based score treats every vote identically and selects a unique winner if
all included prediction tools are able to make a prediction. Since we also include the
I-Mutant2.0 prediction results, we obtain an odd number of tools. In cases, where tools
fail to return a prediction result and thus, no consensus decision is possible, we annotate
the amino acid substitution with no consensus.
Within the 3D structure visualization, the mutated residues can be colored according to
their pathogenicity consensus score via the defined coloring method
COLORING PATHOGENICITY (see Figure 4.3).
The update and maintenance of the installed prediction tools is straightforward, since
this only implies the installation of the newer software version on the compute server
as well as a potential server script adaption without substantial re-implementation
in BALL-SNP. In consequence, users are not forced to update their local BALL-SNP
versions to receive updated predictions.
Moreover, the constructed compute server as well as the implemented interfaces to
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request and to process the corresponding response in BALL-SNP, can easily be extended
to incorporate further available, stand-alone software tools for the disease-association
analysis of nsSNVs.
Abbildung 4.3: 3D structure of the protein encoded by SMYD2. The amino acid sub-
stitutions introduced by nsSNVs are visualized in ball-and-stick repre-
sentation and colored due to their calculated pathogenicity prediction
consensus.
4.5 Integration of available database information
Experimentally gained knowledge about nsSNVs is deposited and curated in different
databases [98]. Some of these databases provide additional information concerning the
pathogenicity and clinical significance of a nsSNV (details see Section 2.2 and the followi-
ng). To make use of this knowledge, we include information from SwissProt/UniProtKB
[26] and ClinVar (dbSNP) [23] within BALL-SNP. In particular, SwissProt/UniProtKB
collects human polymorphisms and disease mutations (annotated in the HUMSAVAR
document) assigned according to literature reports on probable disease association.
ClinVar is based on the dbSNP [5] and reports human variations while providing clinical
significance information.
Besides, we also incorporate data on drug targets curated in DrugBank [28]. The
knowledge whether the corresponding protein of a query gene is already a target for
medical treatment may provide users with helpful information concerning probable
effects of mutations within the target protein, such as e.g. the loss of drug binding.
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Information concerning protein interaction sites and in particular, residues participating
in these, additionally provide elementary information on protein functions and putati-
ve dysfunctions. We therefore integrated The Database of Protein interaction SITEs
(PiSITE) (Section 2.10.6). Since PiSITE assigns the interaction information on the
residue level, we are able to label mutated residues via COLORING INTERACTION, accor-
dingly. Since interaction residues close to substituted amino acids might be influenced by
these, we additionally offer the possibility to color the complete protein representation
according to the available interaction information (see Figure 4.4).
Moreover, the Exome Aggregation Consortium (ExAC) provides summary data of
exome sequencing projects, freely available for the scientific community [58] (details
in Section 2.10.7). We also include these summary data, since the comprised nsSNVs
may indicate common polymorphisms inherited in the human population or variations
called dependent on the SNP calling technique.
Figure 4.5 exemplarily displays the table representing the integrated information from
databases, I-Mutant2.0 (stability prediction) and pathogenicity prediction tools.
Abbildung 4.4: 3D representation of the protein encoded by MEF2A with residues
participating in interaction sites labeled in pink.
In cases where database information concerning pathogenicity and/or clinical relevance
is available for a given nsSNV, these information is also incorporated into the calculated
pathogenicity consensus score for this particular nsSNV (see Section 4.4.3). Since
experimentally gained knowledge on the functional impact of an nsSNV is usually more
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Abbildung 4.5: Table with generated information from different databases, I-Mutant2.0
and pathogenicity prediction tools for SMYD2.
reliable than the predicted impact, the pathogenicity consensus prioritizes pathogenic
database information. Benign annotated nsSNVs, however, are treated with equal
priority to generated prediction results. In the past, these nsSNVs particularly received
re-annotations with disease association in some cases, since experimental studies and
available expert knowledge increase. We identified, for example, some variants in the
neutral VariBench data set of Thusberg et al. [79] created in 2011, as disease-associated,
with entries in the HGMD [6] available in 2014.
To enable a straightforward update and maintenance policy, the integrated data sources
are parsed and preprocessed via sophisticated Python scripts included in BALL-SNP’s
additional data directory. The generated, predefined data formats then are parsed in
the C++ implementation via the DatabaseParser class. In consequence, a change in a
data source will not affect the C++ implementation of BALL-SNP.
Currently, we are focusing on selected important databases that report nsSNV patho-
genicity. The embedded database module, however, can easily be extended to include
further databases and annotation sources.
4.6 Predicting binding pockets
In addition to data mining information on pathogenicity from databases and in silico
prediction, further information may provide clinicians essential input. Among these,
the proximity of nsSNVs to functional sites such as binding pockets for ligands plays
a crucial role. BALL-SNP predicts active sites, which often are located in the largest
surface cleft, based on the Putative Active Sites with Spheres (PASS) method [101], that
uses probe spheres to characterize regions of buried volume on a protein surface [98].
Based on size, shape, and burial extent of these volumes, positions, which putatively
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represent binding sites, are identified.
The basic algorithm was already implemented in BALL, however, not used in the
current version. We extended the existing code to visualize the predicted active sites as
spheres in BALL-SNP and consequently represent the center of the detected binding
pockets (see Figure 4.6).
Abbildung 4.6: The MAP2K3 protein in Solvent-Excluded-Surface (SES) representation
including the center of predicted active sites (purple spheres).
4.7 Cluster analysis of nsSNVs
Several mutated residues in one protein may have a synergetic effect on the cause
and severity of a disease phenotype [98]. The detection of putative quantitative effects
requires 3D structural information and visualization. To support the visual inspection
of spatial relations, we implemented a hierarchical bottom-up clustering performed on
the 3D structure of the encoded protein and the amino acid substitutions introduced by
nsSNVs. The applied distance metric refers to the Euclidean distance of the mutated
residues Cα-atoms. The linkage criterion to determine the distance between sets of
amino acid substitutions was defined according to the average linkage variant. Details
on hierarchical clustering and the linkage strategies are explained in Section 2.10.5.
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The cluster analysis is implemented in the SNPClustering class within the BALL core.
To store required cluster properties such as members or the distance at which two
clusters were merged into the current, we defined a SNPCluster class serving as a data
container for one single cluster.
Moreover, proteins comprise polypeptide chains, also known as protein subunits. These
subunits may be identical, homologous or dissimilar and dedicated to different tasks.
Amino acid substitutions in one subunit can also reside in identical subunits of the
protein. Since the naturally occuring form of some proteins not only consists of one
but several subunits, nsSNVs can introduce substitutions in several identical subunits,
simultaneously.
The spatial analysis of mutated residues within one subunit as well as among all subunits
of the protein might add critically to the understanding of synergetic effects introduced
by nsSNVs. To be able to differentiate between mutations in identical protein subunits,
we introduced the notation wild type amino acid + residue position + mutant amino
acid + subunit, e.g. G56S A for the substitution of glycine at position 56 in subunit A
to serine.
Since distance thresholds depend on the size of the protein and its folded 3D structure
and thus, are difficult to generalize, we provide the user with all possible distance
thresholds and offer the possibility to visualize the resulting clusters, respectively.
The results of the cluster analysis are represented in tabular format on BALL-SNP’s
information page (Figure 4.7).
Abbildung 4.7: The cluster analysis results with all possible distance thresholds are
presented in a tabular format on the information page.
Users can choose which threshold to visualize within the 3D structure and can print
the corresponding clustering mutated residues via links on the information page (see
Section 4.8). Figure 4.8 examplifies the printing of the cluster affiliation of specific
amino acid substitutions at a certain distance threshold.
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Abbildung 4.8: The members of the clusters at a specific threshold can be printed
via links on the information page. The notation of an amino acid
substitution is defined as wild type amino acid - residue position -
mutant amino acid - chain of the protein.
Within the 3D structure visualization, the clustering mutations can be labeled accor-
ding to their cluster affiliation via the defined coloring method COLORING CLUSTER,
exemplified in Figure 4.9.
Abbildung 4.9: Glycerol-3-phosphate dehydrogenase 1-like protein encoded by the
GPD1L gene in cartoon representation with highlighted results of the
cluster analysis at a distance threshold of 26A˚.
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4.8 Representation of generated information - the
information page
In the previous sections, we generated information critical for the assessment of nsSNVs
as candidates for clinical studies. To allow a user-friendly, well-structured representation
of all these generated information without extensive expert knowledge of the underlying
implementation, we use established web technology standards to provide a QtWebKit-
based HTML environment. This environment was adopted from PresentaBALL, a
package for presentations and lessons in structral biology, embedded as a plugin within
BALL/BALLView [102].
Though, we also aim at an intuitive interaction with information content and a clearly
arranged representation, the demands BALL-SNP poses on such an interface, differ
compared to those of PresentaBALL. In consequence, we implemented a novel interface
class called DatabaseInterface. This C++ interface is assigned two main tasks:
representation of the generated information via an HTML interface widget in BALLView
and intuitive techniques to interact with and visualize these information in the 3D
structure.
The content of the HTML interface widget is parsed, prepared and generated by
the DatabaseParser class and includes for example the information from different
embedded databases (see Section 4.5) and cluster analysis results (see Section 4.7).
Since the information page is already visualized at the start of a running BALL-SNP
instance, when no SNV data was loaded yet, the DatabaseParser has to generate an
updated instance of this HTML interface widget with the calculated information after
SNV input data was loaded.
Besides, the user is able to trigger visualization events via standard HTML hyperlinks
providing complete access to the Python interface of BALL. The link syntax based on
standard HTTP query strings refers to:
BALL-SNP/BALL/data/DatabaseInterface/database index.html?
action= Python function to call
&module=common functions
We restrict the user interaction, however, to modify the residue coloring according
(e.g. COLORING PATHOGENICITY) to specified properties (e.g. PROPERTY PATHOGENIC,
PROPERTY BENIGN), creating predefined visual representations such as Solvent-Excluded-
Surface (SES), and to the corresponding reset functionality. For this purpose, we
added corresponding functions to the collection of predefined Python functions (com-
mon functions), which are called from the HTML interface widget and provided from
PresentaBALL:
• colorDatabaseInfo(): color mutated residues according to generated database
info
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• resetDatabaseInfo(): reset coloring of mutated residues to standard
• setClusterThreshold(distance): set distance threshold to join two clusters
• colorClusterInfo(distance): color mutated residues according to their cluster
affiliation at a specific distance
• resetClusterInfo(): reset cluster coloring of mutated residues to standard
• colorInteractionInfo(): color mutated residues participating in interaction
sites
• resetInteractionInfo(): reset coloring of mutated residues to standard
• colorSystemInteractions(): color the complete 3D representation of a protein
based on available interaction site information
• resetSystemInteractions(): reset the protein coloring to standard
• createSESModelAndHighlightSNPs(): create SES model representation for pro-
tein and highlight mutated residues
• removeSESModel(): remove created representation of SES model from 3D view
In contrast to PresentaBALL, the HTML interface is fully integrated within BALL/
BALLView without plugin activation requirements and plugin dependent usage. To
avoid complexity, the allowed interactions are restricted to defined use-case scenarios
valid in the analysis of nsSNVs.
4.9 Application Scenarios
A valid and high-quality data set is essential when analyzing the phenotypic effect of
nsSNVs on human health. To avoid artifacts, that may arise from using artificially
generated data sets and to prove the benefits of the developed tool BALL-SNP, we
applied it to clinical, high-quality data of DCM patients (details in Section 2.12.1) as
well as cancer data from one patient diagnosed with breast cancer.
In general, there are two practical scenarios based on NGS data, which are, to the best
of our knowledge, not implemented in the previously existing methods: the assessment
of the effect of several nsSNVs within a single protein, and the contribution of nsSNV
sets to ligand binding or protein stability. BALL-SNP is able to support the user in
selecting candidate nsSNVs for further analysis and finding possible solutions in both
scenarios.
In the following, we outline BALL-SNP’s rich functionality and ability to assess the
effect of nsSNVs in different use-cases.
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Figure 4.10 demonstrates the general pipeline BALL-SNP processes when loading a
delivered input file.
4.9.1 Analysis of cardiomyopathy data
The results presented in this section have already been published in [98].
Within the high-quality NGS data set of 639 patients suffering from DCM [72], we
identified three cases exemplary for the previously mentioned practical scenarios in NGS
data analysis [98]. Genes JUP, VCL and SMYD2 revealed nsSNV cluster in potentially
interesting locations. In particular, the nsSNVs of the DCM data within these genes
reveal no pathogenic annotations in available databases.
Analysis of nsSNVs in JUP The gene JUP coding for junction plakoglobin is involved
in cell junction, which influence the arrangement and function of cells within a tissue.
In particular, JUP is involved in arrhythmogenic right ventricular dysplasia (ARVD),
a congenital heart disease [103].
For the example of JUP, we exemplarily process the pipeline of an input file within
BALL-SNP step by step.
An exemplary input file for BALL-SNP in BALLformat (see Section 2.10.2) is shown
below for the gene JUP :
PDB: 3IFQ
JUP NM 002230 T739A chr17 39912019 .
JUP NM 002230 N690S chr17 39912444 .
JUP NM 002230 V648I chr17 39913771 .
JUP NM 002230 M697L chr17 39912145 rs1126821
JUP NM 002230 R142H chr17 39925713 rs41283425
JUP NM 002230 I348T chr17 39921186 .
JUP NM 002230 L527I chr17 39915041 .
JUP NM 002230 R176W chr17 39925402 .
JUP NM 002230 R203C chr17 39925321 .
The gray-colored text line is optional.
Based on this input file, BALL-SNP first checks automatically for available 3D structures
of the protein encoded by gene JUP, if no PDB identifier was provided, and/or downloads
the PDB structure. Next, the 3D structure is visualized in the 3D view of BALL-SNP.
Since the calculation requires few minutes, the user can then decide whether to compute
the pathogenicity consensus and protein stability predictions for each nsSNV in the
input file or skip this step. In the case of JUP, 4 of the 9 inherited nsSNVs reveal a
disease-association in the consensus pathogenicity prediction (details see Section 4.4.3).
Table 4.1 lists the introduced amino acid substitutions and the calculated pathogenicity
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Abbildung 4.10: General pipeline processed in BALL-SNP for a given input file.
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consensus as well as the predicted protein stability change. The database info, generated
in the next step, however, contains only information for the amino acid substitution
M697L, namely a non-pathogenic clinical significance.
Tabelle 4.1: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in JUP.
amino acid substitution pathogenicity consensus protein stability
R142H pathogenic decrease
R176W pathogenic decrease
R203C pathogenic increase
I348T pathogenic decrease
V648I benign decrease
N690S benign decrease
M697L benign decrease
T739A benign decrease
In further steps, mutated residues are labeled, binding pockets predicted and a cluster
analysis on all amino acid substitutions is performed, simultaneously. Based on this
information, users can highlight the mutated residues in the visualization, accordingly.
Figure 4.11 illustrates the result of the cluster analysis at a threshold of 24A˚. The
coloring of the amino acid substitutions is defined by their cluster affiliation.
The combination of both, the generated pathogenicity consensus and the cluster analysis,
indicate a synergetic influence on the protein’s function of several mutated residues.
Mutations with a pathogenic prediction are clustering and in particular, benign predicted
substitutions also show a close neighborhood.
In addition, the center of putative active sites were labeled with purple spheres within
the 3D visualization. Interestingly, the amino acid substitution L527I indicates proximity
to a predicted binding site (see Figure 4.12).
The nsSNVs in our data set, identified in the coding region of JUP obtained either no
annotation or a benign one. Based on the performed analysis with BALL-SNP, however,
putative synergetic effects of the introduced amino acid substitutions are uncovered,
identifying these nsSNVs as promising candidates for further clinical studies.
Analysis of nsSNVs in VCL VCL codes for vinculin, an actin filament-binding pro-
tein, involved in both, cell-matrix and cell-cell adhesion. VCL has been reported to
be associated with DCM, a congestive heart failure [99]. Database search yields no
annotations for the nsSNVs in VCL from our data set.
In contrast, the calculated pathogenicity consensus associates 6 of 9 nsSNVs as disease-
linked and I-Mutant predicts all except one to decrease protein stability (see Table
4.2).
Interestingly, BALL-SNP identifies, that amino acid substitutions corresponding to
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Abbildung 4.11: The wild type structure of the protein encoded by JUP is displayed
in the cartoon representation (gray), while the inherited amino acid
substitutions are colored according to their cluster affiliation.
Tabelle 4.2: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in VCL.
amino acid substitution pathogenicity consensus protein stability
R230H pathogenic decrease
H363R pathogenic decrease
A413T benign decrease
I519L pathogenic decrease
R586W pathogenic increase
V658A no consensus decrease
R759Q pathogenic decrease
A922V benign increase
N1010K pathogenic decrease
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Abbildung 4.12: Cutout of the solvent-excluded surface of JUP. The purple sphere
represents the center of a predicted binding site. The mutation L527I
(highlighted in yellow) is located within the detected, putative binding
pocket [98].
nsSNVs, cluster together in the protein structure at a threshold of 19A˚(see Figure 4.13).
The mutations I519L, R586W and V658A cluster with Cα-atom distances between 15
to 19A˚, respectively. Except V658A, the substitutions obtained a disease-association
in the pathogenicity consensus. H363R and R759Q are in close neighborhood with a
Cα-atom distance around 19A˚. In addition, both mutations are predicted to decrease
protein stability and are linked to disease.
Since we are also able to detect clusters between the different subunits of a protein, we
identified R230H in chain B and A922V in chain A to be located close to each other
(Cα-atom distance of 19A˚). Mutations at the interface of protein subunits may critically
influence the stability of the protein, since they can alter the binding affinity of the
subunits among each other.
The BALL-SNP analysis of the nsSNVs of VCL again contributed important information
not available in state-of-the-art approaches to assess the functional effect of nsSNVs.
Analysis of nsSNVs in SMYD2 SMYD2 codes for a N-lysine methyltransferase, which
methylates both, histones and non-histone proteins. While the database search only
returns either no or benign annotations, 2 of the 7 nsSNVs are consensually predicted
to be pathogenic (Table 4.3).
Furthermore, BALL-SNP impressively shows that several amino acid substitution pairs
introduced by nsSNVs are located next to each other, implying a cumulative effect. The
mutations Y370C and M384V (at a Cα-atom distance of 9A˚) are adjacent in an opposite
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Abbildung 4.13: The 3D structure of the protein encoded by VCL. The wild type
structure of the protein is displayed in the cartoon representation
(gray), while the mutated residues are colored by their cluster affiliation
at a threshold of 19A˚.
Tabelle 4.3: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in SMYD2.
amino acid substitution pathogenicity consensus protein stability
G165E benign increase
V301I benign decrease
V349A benign decrease
Y370C pathogenic decrease
M384V benign decrease
G394C pathogenic decrease
I430M benign decrease
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direction, and both are predicted to lead to decreased protein stability. Furthermore,
the substitutions G394C and I430M are located close to each other (12A˚ Cα-atom
distance) as well as V301I and V349A (16A˚ Cα-atom distance). Interestingly, both pairs
produce opposite predictions of I-Mutant concerning their impact on protein stability.
Abbildung 4.14: Cutouts of the 3D structure of the SMYD2 encoded protein. The
clustering pairs of amino acid substitutions are highlighted in different
colors. The color framed pictures are close-up views of the correspon-
dingly colored mutation pairs. All pairs are located next to each other,
indicating a cumulative effect [98].
Figure 4.14 illustrates these 3D spatial observations, in detail. The overall results of
the hierarchical cluster analysis based on average linkage are shown in Figure 4.15.
In conclusion, BALL-SNP was able to identify promising candidates for further clinical
studies and computational diagnostics in all of the three presented analyses. Based on
these findings, further analyses on the relation to disease traits of the detected nsSNVs
are possible.
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Abbildung 4.15: Cluster analysis of the amino acid substitutions in the SMYD2 en-
coded protein. The protein consists of two chains A and B. Hence,
the mutations are labeled accordingly. Part A: The amino acid sub-
stitutions are highlighted within the protein 3D structure according
to their cluster affiliation. Part B: The overall cluster analysis results
are shown in tabular format on the information page. The red marked
distance refers to the highlighted cluster of mutations in the structural
visualization [98].
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4.9.2 Analysis of breast cancer data
Circulating tumor cells (CTCs) are considered as a valuable liquid tumor biopsy. Espe-
cially for metastatic cancers, CTCs have demonstrated a substantial potential for
prognostic purposes. In an exome sequencing study of 3 CTCs captured from one breast
cancer patient and of the corresponding tumor tissue, we identified genes enriched with
mutations, that overlap in all four samples (study currently unpublished). Among these,
especially MAP2K3 and KCNJ12 revealed several nsSNVs and have been described in
the context of various cancers according to literature [104] [105].
For both, however, no 3D structure is available from the PDB. In such cases, BALL-SNP
offers an automated 3D model search of the corresponding protein via a compute server
and the database of comparative protein structure models, ModBase (Section 4.3).
BALL-SNP was able to detect 3D models in ModBase with target-template alignments
of about 84% (MAP2K3 to template 3ENM) and 90% (KCNJ12 to template 3SPC)
sequence identity as well as reliable e-values and DOPE scores, respectively. In conse-
quence, we were able to analyze the spatial relationship of the detected variants in the
corresponding proteins of MAP2K3 and KCNJ12 with BALL-SNP.
MAP2K3 In the encoded protein of MAP2K3, variant R264H resides close to a
predicted active site center and thus, probably has an influence on the binding affinity of
MAP2K3 protein (see Figure 4.16). Interestingly, both detected amino acid substitutions
additionally revealed a disease-associated pathogenicity prediction consensus (see Table
4.4). Further studies on putatively altered binding affinities due to these mutations are
required to guide drug target analyses.
Tabelle 4.4: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in MAP2K3.
amino acid substitution pathogenicity consensus protein stability
R67W pathogenic decrease
R264H pathogenic decrease
KCNJ12 Within the found 3D model of the ATP-sensitive inward rectifier potas-
sium channel 12, encoded by KCNJ12, the inherited nsSNV-introduced amino acid
substitutions cluster together, impressively (see Figure 4.17).
Variants D173N, A185V and M302I are located next to each other with pairwise
Cα-atom distances between 18A˚ and 16A˚, respectively. Hence, these variants may
putatively add to a quantitative effect on a dysfunction of the corresponding protein.
Besides, D173N and I100V also cluster with a Cα-atom distance of 21A˚. All mentioned
mutations are furthermore predicted to decrease protein stability. In addition, 4 of 6
amino acid substitutions are predicted to be pathogenic (see Table 4.5).
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Abbildung 4.16: SES representation of the found 3D model of MAP2K3 encoded protein.
The included amino acid substitution R264H is located close to a
putative active site. The purple sphere represents the center of a
predicted binding pocket.
Abbildung 4.17: 3D model of KCNJ12 encoded protein in cartoon representation. The
majority of the nsSNV-introduced amino acid substitutions cluster
within the 3D structure. The variants D173N, A185V and M302I are
located close to each other with pairwise Cα-atom distances of 18A˚ and
16A˚, respectively. In addition, D173N and I100V are close neighbors
with a Cα-atom distance of 21A˚. S343L and R43H at least reveal a
Cα-atom distance of 32A˚.
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Tabelle 4.5: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in KCNJ12.
amino acid substitution pathogenicity consensus protein stability
R43H pathogenic decrease
I100V benign decrease
A185V pathogenic decrease
D173N pathogenic decrease
M302I pathogenic decrease
S343L benign increase
In conclusion, the results obtained in the BALL-SNP analyses hint to a disease-relation
of the studied nsSNVs. Although further validation studies are required, these results
may contribute to the selection of clinically relevant candidate nsSNVs.
4.9.3 Analysis of interaction sites
Unfortunately, annotations of genetic variants and in particular, their introduced amino
acid substitutions are often missing. In consequence, we consider multiple data sources
and calculate several properties of mutated residues within BALL-SNP. For the applied
clinical data sets, however, no interaction site information from PiSITE (Section 2.10.6)
was available. To be able to nevertheless demonstrate BALL-SNP’s capability to make
use of this information, we selected a representative protein with amino acid subsitu-
tions at residues with available PiSITE interaction information from the UniProtKB
(Section 2.2.2). The gene MEF2A encodes for the myocyte-specific enhancer factor 2A,
a transcriptional activator with specific binding to the MEF2 element [106]. It mediates
cellular functions in skeletal and cardiac muscle development as well as in neuronal
differentiation and survival.
We selected four amino acid substitutions annotated in the UniProtKB to demons-
trate BALL-SNP’s interaction labeling functionality. In addition, we computed the
pathogenicity and protein stability predictions (see Table 4.6).
Tabelle 4.6: Pathogenicity consensus as well as prediction of the resulting protein stability for the
amino acid substitutions introduced by nsSNVs in MEF2A.
amino acid substitution pathogenicity consensus protein stability
R269A pathogenic decrease
K270A pathogenic decrease
L273A pathogenic decrease
V275A pathogenic decrease
The chosen nsSNVs are annotated in the UniProtKB to reduce trancriptional activity
82
4 BALL-SNP: A tool to identify candidate nsSNVs
when pairwise associated with each other. Figure 4.6 represents the 3D structure of the
endcoded protein with residues participating in the protein’s interaction sites colored in
pink. The amino acid substitutions introduced by the selected nsSNVs are additionally
visualized with their SES and colored in blue. The mutated residues at position 273
and 275 participate in an interaction site of the protein and thus, are colored in pink
including their SES. In combination with the available annotations in UniProtKB, the
pathogenicity consensus and I-Mutant’s stability change predictions, the nsSNVs L273A
and V275A indicate disease-relevance, which should be further examined in clinical
studies.
Abbildung 4.18: 3D representation of the protein endoced by MEF2A. Residues with
available information concerning their participation in protein inter-
action sites are colored in pink. Mutated residues are colored in blue,
except they contribute to an interaction site (pink color).
4.10 Conclusion
The analysis of the genotype-phenotype relation and in particular, of the influence of
nsSNVs on protein stability and function, is essential in human health care. In spite of
the fact, that the majority of common diseases such as cardiomyopathy are caused by
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accumulation of several nsSNVs, computational methods to analyze cumulative nsSNVs
and their putative quantitative contribution to an observed pathogenic phenotype
are missing. In consequence, the validation of the clinical relevance of nsSNV spatial
interactions is limited.
Our tool BALL-SNP combines genetic and structural information to provide scientists
the possibility to get deeper insights on the potential effects of accumulated mutations in
proteins. BALL-SNP enables the assessment of the impact of nsSNV clusters on protein
stability, and consequently assists the selection of candidate nsSNVs for experimental
validation. It is based on a standard molecular modelling framework, allows the use of
standard NGS output, embeds important nsSNV annotation databases and performs
nsSNV cluster analysis.
Although further improvement is needed to meet requirements of the clinical application,
BALL-SNP already makes an important contribution to the existing instruments of
candidate nsSNV analysis.
Besides nsSNV sets inherited in one gene, nsSNVs in different genes can imply synergetic
events [107]. To be able to study these, we developed a multi-scale analysis approach,
presented in the next chapter.
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multiple genes
Traditional computational approaches predict the influence of nsSNVs on pathogenicity
for single variants. The impact of nsSNVs on a patient’s phenotype, however, can arise
from multiple factors such as e.g. gene-gene and gene-environment interactions [20].
In the previous chapter, we presented BALL-SNP, a tool to assess the functional impact
of nsSNV sets in one gene for the identification of candidate nsSNVs in NGS data. Since
the genetic basis of most common diseases refers to multiple genetic factors working in
aggregate [16], sets of genes inhering nsSNVs may also exhibit synergetic effects.
Previous studies analyzed the occurrence and characteristics of compensatory mutations
[108], though there might also be cumulative effects of mutations, packing single benign
effects together to an observable disease phenotype. More precisely, benign-annotated
nsSNVs in combination might be responsible for a pathological effect. Westphal et
al., for example, studied congenital disorders of glycosylation and identified a mild
polymorphism in ALG6 putatively exacerbating an already severe pathogenic phenotype
caused by PMM2 dysfunction [109]. This phenomena often is denoted by epistatis, in
essence defined as the interaction between genes. In available literature, however, this
term is confusingly and even conflictively used according to Heather J. Cordell [110].
In fact, a differentiation of genes and proteins in the context of interaction analysis
is exhausting. In this chapter, we refer to the analysis of nsSNVs in multiple genes
including the analysis of introduced amino acid substitutions in the encoded proteins
avoiding the term epistasis. We study the accumulations of nsSNVs on the genomic
level, while examining their interactions on the protein level.
Since biological systems are driven by complex biomolecular interactions [9], the study of
putative synergetic events affecting a patient’s phenotype requires a multi-scale analysis
comprising 3D context, interaction information and functional cascades. To address this
issue, we extended the traditional pathogenicity prediction approach by the analysis of
nsSNV-affected genes and their mutated proteins in terms of available 3D structures,
pathway analysis and subcellular localization on the example of a high-quality clinical
data set of cardiomyopathy patients. The conducted multi-scale pipeline is summarized
in Figure 5.1.
The work presented in this chapter will be published under [111].
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Abbildung 5.1: Schema for multi-scale analysis of nsSNVs. The traditional approach of
pathogenicity prediction of single nsSNVs is extended by more complex
levels such as rule mining to detect nsSNV sets in patients. On the top
level, pathway analysis as well as subcellular localization are applied to
study the pathogenic impact of multiple nsSNVs [111].
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5.1 Adaption of association rule learning to identify genes
with synergetic nsSNVs
Human individuals frequently carry more than one single nsSNV even within one gene.
Beyond this, genes and their encoded proteins interact with each other.
To discover strong relations between variables in large data sources, association rule
learning is generally applied. Association rule learning uncovers hidden relationships
within the tested data by formulating association rules, while using different measures
of interestingness to quantify the quality of the generated rules (details see Section
2.11.1).
Via association rule learning, we studied whether there are frequent combinations of
nsSNVs within our DCM data set (see Section 2.12.1) and a healthy control cohort
based on the general population of the 1000 Genomes Project (see Section 2.12.2).
The DCM data comprises 76 genes inhering 842 nsSNVs from 639 DCM patients. We
applied the R package arules [60] with confidence threshold 0.8 and different levels of
support, starting with at least 0.5.
In fact, we were able to identify associated combinations of nsSNVs with high support
and significant confidence values in both, single genes and multiple genes. In the DCM
data, we detected frequent combinations of nsSNVs within the single genes MYPN,
CACNA1C, DMD, ADRB2 and RBM20 with high support and significant confidence
values. Table 5.1 lists the detected nsSNVs significantly associated within one gene.
The nsSNV combinations in RBM20 and CACNA1C are even found in at least 90% of
all patients.
Tabelle 5.1: Significantly associated nsSNVs in single genes with confidence of at least 0.8.
Gene nsSNVs DCM patients with nsSNVs
ADRB2 G16R, E27Q 64%
CACNA1C M869V, K1893R, P1868L 96%
DMD D878G, R2933Q 72%
MYPN S691N, S707N 72%
MYPN F628L, S691N, S707N, P1135T 70%
MYPN F628L, S803R, S691N, S707N,
P1135T
67%
MYPN S803R, S691N, S707N, P1135T 67%
RBM20 E1223Q, W768S 98%
Since experimental validation is limited, we rely on experimental knowledge deposited
in available databases. According to database entries in the HGMD (Section 2.2.3)
and UniProtKB (Section 2.2.2), RBM20 is already related to DCM and CACNA1C
to the Timothy and Brugada Syndrome, which is a genetic disease characterized
by an abnormal electrocardiogram. MYPN, that incorporates the most identified
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associated nsSNV accumulations, is linked to different forms of cardiomyopathies
(familial, hypertrophic, dilated). ADRB2 participates in signal transduction and namely
in the adrenergic signaling in cardiomyocytes. DMD is involved in several pathways
relevant for cardiac diseases such as DCM, hypertrophic cardiomyopathy (HCM),
arrhythmogenic right ventricular cardiomyopathy (ARVC) and viral myocarditis. All
identified nsSNV associations, however, are annotated as benign nsSNVs.
Furthermore, we detected nsSNV combinations in different genes (CACNA1C, SMYD2,
PARVB, KCNE1, RBM20, KCNQ2 and JUP) significantly associated with each other
in the DCM patients. Table 5.2 lists the detailed nsSNV combinations. Using the
corresponding association rule setup, these specific nsSNV - gene combination is not
present in the control cohort. Just SMYD2, PARVB, KCNE1 and JUP revealed an
association in the healthy controls.
Tabelle 5.2: These associated nsSNV combinations in seven different genes are detected in more
than 70% of all patients with confidence of 0.8 and higher. Interestingly, the 26 patients
without identified disease nsSNVs share these combinations.
Gene Expression nsSNV set
CACNA1C Heart, brain, ovary, etc. M869V, K1893R, P1868L
SMYD2 Heart, brain, etc. G165E
PARVB Heart, skeletal muscle V6A
KCNE1 Heart, lung, etc. S38G
RBM20 Heart E1223Q, W768S
JUP Heart M697L
The nsSNVs in CACNA1C and RBM20, could even be detected in 90% of all DCM
samples. According to a large-scale analysis of the human transcriptome in 2004, all
of the associated genes revealed significant expression in heart [112]. The majority of
detected genes with associated combinations is already known in the context of diseases
such as Brugada Syndrome, Long QT Syndrome, Naxos Disease and different stages of
DCM. In contrast, all association rule detected single nsSNVs within these genes are
annotated as benign, except the N749T mutation in KCNQ2, which has currently no
available annotations. Figure 5.2 compares the information annotations of all genetic
variants within the DCM data set with the association rule detected.
Among the 639 DCM patients, we identified 26 without already known or annotated
disease-associated nsSNVs. The 26 DCM patients mainly inhere benign and not anno-
tated variants. Interestingly, the intersection of their inherited nsSNVs revealed exactly
the detected associated nsSNV combinations in CACNA1C, SMYD2, PARVB, KCNE1,
RBM20, KCNQ2 and JUP.
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Abbildung 5.2: Comparison of all genetic variants within the DCM data set and the
association rule (AR) detected. Except one not annotated AR variant,
all other AR variants have neutral annotations available [111].
5.2 Network analysis of genes with associated nsSNVs
Due to the growing availability of high throughput biological data, the analysis of
molecular networks gained significant interest. In addition, the incorporation of expert
knowledge from gene ontology (GO) and biochemical pathways in e.g. genome-wide
association studies (GWAS) has been shown to provide more meaningful results [9].
In consequence, we used several information sources to determine the biological and
functional connections of the detected, associated genes with nsSNV combinations. The
databases queried are: The STRING database [62], the Gene Ontology Annotation
(GOA) database [65] and the KEGG PATHWAY database [66] (details see Section
2.11).
The network analysis splits into functional interaction and biological intersection of the
associated nsSNVs in different genes. Referring to the corresponding GO terms of the
genes with associated nsSNV combinations, the majority participates in protein binding,
voltage-gated ion channel activity and transport. A mutation of residues involved in
complex interaction networks can critically influence large interaction cascades by
spreading the implemented loss across the network.
Besides the biological connections among the associated nsSNVs, we also investigated
their topological characteristics within the human interaction network. To detect
putative interaction hubs, we determined betweenness and degree for each node in
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the human STRING network using the R package igraph [113]. The degree of a node
identifies the number of edges connected to the node, whereas the node betweenness is
an indicator of the nodes centrality in the network. The calculations were based on the
downloadable version of the human STRING network including scored links between
proteins and interaction types for protein links, available at http://string-db.org/
(version v9 05 and v9 1, November 2014).
To provide more insight into the biological intersection and functional interaction as
well as combine the corresponding findings, we visualized these genes with related genes
and highlighted GO overlaps within the resulting networks using Cytoscape [91] (see
Figure 5.3). The edges in the network refer to available interactions between their nodes.
CACNA1C, JUP, SMYD2, PARVB and KCNQ2 are directly connected to large hubs
within the STRING human network.
In addition, KCNE1, KCNQ2 and CACNA1C interact functionally with each other
[114]. KCNE1 attenuates the current amplitude of the KCNQ2 channel subunit and
slows its gating kinetics [115]. According to the KEGG PATHWAY database, KCNE1
is part of the adrenergic signaling in cardiomyocytes. A perturbation of its channel
function by inherited mutations results in increased susceptibility to cardiac arrhythmias.
KCNQ2 belongs to the cholinergic synapse and CACNA1C even takes part in both
pathways.
Interestingly, KCNE1, CACNA1C and KCNQ2 are already targets of drugs against
arrhythmia, atrial fibrillation, congestive heart failure, left ventricular hypertrophy and
isolated systolic hypertension according to DrugBank entries [116].
5.3 Structural location of amino acid substitutions
The protein structure reveals interactions between residues which are distant in primary
sequence but close in 3D space. The effect of an nsSNV critically depends on the
structural location of the mutated residue, especially if it is buried in the hydrophobic
core or exposed on the protein surface [117]. In particular, disease-associated variants
often affect intrinsic structural features of proteins [118].
First, we selected all proteins within our DCM data set, with a 3D structure available
in the PDB (see Section 2.3). Next, we calculated solvent accessibilities using naccess
(see Section 2.11.5) for the 8 proteins (comprising 46 amino acid substitutions) in our
data set with an available PDB structure to analyze whether disease-associated amino
acid substitutions cluster on the protein surface or at buried sites.
Solvent accessibility provides an intuitive and quantitatively reasonable idea of the
complexity of the molecular interaction network a residue is involved in [67]. The results
confirm the findings of Wang et al. for single nsSNVs [119]: The majority (89%) of
disease-linked mutations introduced by nsSNVs is located inside the protein probably
affecting stability, whereas benign-annotated substitutions mainly cluster on the protein
surface (67%).
90
5 Multi-scale analysis of nsSNV sets in multiple genes
Abbildung 5.3: GO annotations and interactions of associated nsSNVs. The network is
based on the STRING human network. The associated nsSNV genes
reveal great overlap in their GO annotations. Some of them are also
connected to the top ranked hubs within the STRING human network
[111].
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Since previous studies identified the majority of pathogenic nsSNVs to destabilize a
protein’s structure [120], we also analyzed protein stability changes upon mutation
based on I-Mutant2.0 predictions (see Section 2.6). The majority (81%) of substitutions
are predicted to decrease protein stability, independent of their location in the 3D
protein structure (see Figure 5.4).
Abbildung 5.4: Information on nsSNV-introduced mutations in proteins of the DCM
data set with available 3D structure. We distinguish between amino
acid substitutions on the surface of a protein (outside) and buried in
the protein structure (inside) [111].
For five protein structures, we were also able to predict possible binding pockets using
LIGSITEcsc [69]. 8 of 10 mutations at the proteins surface are found close to a predicted
binding pocket using the default parameter settings of 1A˚ grid space and a probe radius
of 5A˚. Interestingly, two of the detected significantly associated nsSNV combinations,
KCNE1 S38G and SMYD2 G165E, are also located close to a putative binding pocket
(see Figure 5.5) of the corresponding protein.
SMYD2 lysine-methylates the tumor suppressor TP53, leading to decreased DNA-
binding activity and subsequent transcriptional regulation activity of TP53 [121].
According to literature, the binding interface of TP53 and SMYD2 is located between
the catalytic SET domain (residue 1-282) and the C-terminal domain [122].
5.4 Subcellular localization of mutated proteins
For visualizing and analyzing the localization of the proteins encoded by genes with
nsSNVs, we used the CELLmicrocosmos 4.2 PathwayIntegration (CmPI) (see Section
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Abbildung 5.5: 3D structures of the encoded proteins of KCNE1 and SMYD2. KCNE1:
SES of KCNE1 encoded protein with the mutated S386G in ball-and-
stick representation, highlighted in yellow. The red sphere represents
the center of a predicted binding pocket. SMYD2: SES of the SMYD2
associated protein with the mutated G165E in ball-and-stick represen-
tation, highlighted in yellow. The red sphere represents the center of a
predicted binding pocket [111].
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2.11.7) [70]. In the context of this work, the following databases were queried: BRENDA
[123], GO [124], Reactome [125], and UniProtKB [26].
Based on the previously discussed methods, seven genes were identified showing specific
nsSNV combinations in more than 70% of all analyzed patients: CACNA1C, JUP,
KCNE1, KCNQ2, PARVB, RBM20, and SMYD2. In particular, all of the detected
genes have significant expression in heart. Using CmPI, Homo sapiens-related potential
localizations for these seven genes were acquired using cell component-gene association
data from the aforementioned databases. The associated proteins of these genes show five
potential localizations: nucleus, cytosol, cell membrane, lysosome, and the extracellular
matrix. Moreover, five of them provide multiple potential localizations. An overview
and distribution of these locations can be found in Figure 5.6.
Abbildung 5.6: Subcellular localization chart of all localizations for proteins of the
associated genes [111].
Based on the localization data, the hypothesis can be formulated that these proteins
are assembled in a potential cascade starting from the nucleus, through the cytosol,
entering the cell membrane and proceeding to the extracellular matrix, or vice versa.
This theory is supported by the fact that RBM20 is exclusively localized at the nucleus
and KCNQ2 at the cell membrane, whereas PARVB seems to travel between the
extracellular matrix, the cell membrane and the cytosol.
We visualized the connections of these proteins including the assigned subcellular
locations in Figure 5.7. For the purpose of clarity, Figure 5.7 condenses the detected
interactions to the identified potential cascade.
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Abbildung 5.7: Schematic visualization of the subcellular localization. The red gene
symbols represent the detected associated genes. Besides the subcellular
assignment, interactions between the listed genes are visualized (right
side). Red-labeled edges mark direct connections of associated genes. In
addition to links within one cell compartment, there are also multiple
edges crossing different compartments [111].
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5.5 Conclusion
In this study, we detected patients suffering from cardiomyopathy without identified
disease-associated nsSNVs, but inhering mainly benign-labeled variants. Via association
rule learning, we detected associated combinations of nsSNVs within at least 70% of
all cardiomyopathy patients in the data set. These specific combinations could not be
identified as associated in the control cohort of healthy humans, which hints to disease
relevance, however requires further analysis. Due to the lack of prediction tools able to
assess a cumulative effect of nsSNVs in multiple genes, a pathogenicity prediction for
the identified associated nsSNVs was not possible. Furthermore, only for two of the
identified associated nsSNV genes, KCNE1 and SMYD2, a 3D structure of the encoded
protein was available. For the remaining associated genes, even an adequate template
for structural modelling was missing. Interestingly, the associated nsSNVs in KCNE1
(S38G) and SMYD2 (G165E ) are located at the surface of the encoded protein close
to predicted binding pockets.
In addition, we studied available pathway information including GO annotations and
analyzed interaction networks. Proteins might act at different stages of the same pa-
thway contributing quantitatively to the progressive dysfunction of the pathway until
a disease phenotype is observed. Both genes in Westphal’s study [109], for example,
encode enzymes involved in a different part of the post-translational modification
process without a direct interaction. KCNE1 and CACNA1C as well as KCNQ2 and
CACNA1C participate in the same pathways and mainly contribute to voltage-gated
ion channel activity and transport. Ion channels are key components in a wide variety
of biological processes, such as muscle contraction (e.g. cardiac muscle contraction),
epithelial transport of nutrients and ions or T-cell activation. A number of genetic
disorders (e.g. Long QT syndrome, Brugada syndrome) are related to ion channel
dysfunctions.
Groh et al. [126] created a network based on the combination of diseases and asso-
ciated genes from the Online Mendelian Inheritance in Man (OMIM) database [114].
According to this network, disease genes not necessarily refer to hubs and are even
often non-essential. JUP and PARVB are involved in cell junction organization and
interact as well as SMYD2 directly with the top-ranked hubs within the STRING
human network. Cell junctions play a major role in communication between neighboring
cells and cell stress reduction.
Furthermore, the subcellular localization revealed the seven proteins to form a potential
cascade: RBM20 is only found in the nucleus, SMYD2 travels between the nucleus
and the cytosol, and the other five genes are mostly associated to the cell membrane,
where PARVB shows potential localizations between the extracellular matrix, the cell
membrane and the cytosol.
Finally, all systematic analyses point to a connection of the detected genes featuring
associated nsSNVs - in functionality as well as in their contribution to biological pa-
thways. Moreover, the specific nsSNV combinations identified as significantly associated
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in the DCM patients could not be detected associated within the healthy control
data. In a next step, further association studies on even larger patient cohorts with
cardiomyopathies are required to validate the identified nsSNVs. Additional studies
on patients with phenotypes different from cardiomyopathies, in particular, can assess
nsSNV specificity.
The constructed multi-scale analysis pipeline for nsSNV sets in multiple genes supports
the computational study of synergetic effects and their impact on pathogenicity. We
demonstrated this on the example of a cardiac phenotype, however, the analysis can be
likewise applied to other diseases such as cancer.
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6 Discussion and Conclusion
Advances in high-throughput DNA sequencing techniques have enabled the reliable
detection of individual sequence variants in the human genome [1]. Understanding the
role of genetics in disease has become a central part of medical research. The decryption
of the genotype-phenotype relation and in particular, the study of the pathological
effect of genetic variants such as nsSNVs, are increasingly important in human health
care. The analysis of NGS data, however, still remains a challenge. In particular, the
interpretation of pathogenicity of single variants or combinations of variants is crucial
to provide accurate diagnostic information or guide therapies.
Since the amount of identified nsSNVs is growing rapidly, while the experimental
analysis to gain knowledge concerning their disease association is laborious and time-
consuming, computational approaches have been developed to predict the functional
impact of nsSNVs in silico.
In a comprehensive evaluation study of available methods to computationally predict the
pathogenicity of nsSNVs, we uncovered several drawbacks of currently existing predic-
tion tools with respect to performance, congruency, applicability and clinical relevance.
The major limitation, however, denotes to the underlying ’one-SNV, one-phenotype’-
paradigm. Contrary to Mendelian disorders, common diseases such as diabetes or cancer,
are caused by a varying number of genetic alterations and environmental factors. Typi-
cally, a human individual inheres more than one nsSNV, and beyond single variations,
these individual combinations of nsSNVs may add to pathogenic processes.
In a familial study of healthy parents and their children diagnosed with glioblastoma
multiforme, for example, we could identify variant accumulations detected in specific
genes of the children, not present in their parents [92]. Single variants revealed no
pathogenic phenotype in the parents, their accumulations in the childrens’ genome,
though, might have additively contributed to the observed disease. To the best of
our knowledge, approaches to assess the functional effect of nsSNV sets are currently
limited.
In this thesis, we developed strategies to study both, nsSNVs accumulating in one gene
and nsSNV combinations in multiple genes. The developed approaches have been tested
on high-quality NGS data from 639 DCM patients inhering 842 nsSNVs in 67 genes [72].
In a first step, we implemented a straight-forward approach to discriminate between
disease-associated and neutral nsSNV sets by adaption of existing strategies for single
nsSNV pathogenicity prediction. Our analysis, however, revealed the limitations of
single nsSNV prediction strategies for the application on nsSNV sets.
In the evaluation study of single pathogenicity prediction approaches, we have been able
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to demonstrate the importance of structural information when analyzing the functional
impact of nsSNVs [11]. Hence, we combined genetic and structural information to imple-
ment a software tool - BALL-SNP - to assess the functional impact of multiple nsSNVs
in one protein [98]. BALL-SNP is based on the molecular modelling framework BALL
and its visualization front-end BALLView. It promotes genetic variant interpretation
and identification of candidate nsSNVs for computational diagnostics via nsSNV cluster
and 3D spatial analysis. The input refers to the output of standard SNP annotation
software preventing substantial re-formatting efforts. In addition, we offer a simple
tab-separated format to allow the inclusion of information from several sources.
Since studies on the positive and negative aspects of GWAS revealed the importance
of the integration of already available biological knowledge [9], BALL-SNP incorpora-
tes pathogenicity and clinical significance information available in databases such as
UniProtKB (HUMSAVAR), HGMD and dbSNP (ClinVar). In fact, the information
deposited in different databases or the existing cross-links from one database to others
incorporates inconsistencies complicating information retrieval. The PDB indices for
start and end residues in the UniProtKB, for example, not necessarily correspond to
the actual PDB sequence coverage. But the correct index information is critical to
select the best available 3D structure needed for BALL-SNP analyses. In consequence,
required strategies to uncover and correct these inconsistencies had to be implemented.
Further existing discrepancies in information sources have to be identified and corrected
in future studies to improve current information curation and thus, permit a real gain
of knowledge.
To make use of available pathogenicity prediction tools for single nsSNV, we compute
a pathogenicity consensus score based on the single prediction results for each nsSNV.
Although this majority-vote based consensus score is intuitive and machine learning
methods may perform better, its dependency on the underlying training data is from
our point of view less restrictive in contrast to built models from machine learning
techniques. However, some of the prediction tools base their predictions on models
trained on database data, which may also explain some of their detected limitations.
The applied consensus score particularly improved the statistical performance of single
pathogenicity prediction approaches in the evaluation study. While there are numerous
pathogenicity prediction methods for single nsSNVs available, however, we currently
focus on the integration of available stand-alone software tools to guarantee stable
performance and to be independent of the software maintenance by a third party.
Since we aimed to develop a software tool, which is also usable for non-experts, the
general pipeline processed in BALL-SNP for a given input file with nsSNV information
is designed to automatically delegate the required operations and calculations without
extensive user interaction. The generated information and the 3D structural content are
visualized in a clearly arranged representation including an intuitive user interface. The
availability of a 3D structure, however, represents a critical requirement for an nsSNV
analysis with BALL-SNP. If no PDB structure is available, we offer an automatic
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search for available 3D models. A pipeline for automated 3D modelling requires toolkits,
which are often restricted to non-profit users or even claim a license key for each
modelling process. This contradicts the philosophy of BALL-SNP to be open-source
and usable for both, non-experts and professionals. In consequence, we decided to make
use of databases comprising available 3D models. In fact, the quality of the BALL-SNP
analysis depends on the quality of the 3D model whose quality relies on the availability
of adequate templates. Hence, different 3D models may receive different analysis results.
Experienced users, though, are able to compare different models in BALL-SNP by
root-mean-square deviation (RMSD) calculations and select the most appropriate one
for their studies. Unfortunately, there are cases where no 3D structure and even no
valid 3D model or only small fractions of a protein structure are available. Structural
information proved its significant importance when assessing the effects of nsSNVs on
a protein’s function and stability. In consequence, we prioritize quality results instead
of being able to return any result and accept this limitation. In addition, the PDB is
a collection of 3D information collected world-wide and though sustained efforts to
maintain high-quality data exist, there are unfortunately inconsistent and informal
PDB files, not fully checked for errors. Hence, BALL-SNP might not be able to return
analysis results for each PDB file deposited in the PDB. We, however, implemented
strategies to overcome common inconsistencies such as the correction of the residue
index within the ATOM records in PDB files. Whenever further inconsistencies are
identified, corresponding correction methods will have to be implemented in the future
to avoid failures.
Since BALL-SNP is an open source project and due to its modular architecture, it is
easily extendable and adaptable to include further third party tools or retieve addi-
tional information from data resources. In future versions of BALL-SNP, additional
expert knowledge provided by professional users concerning detected disease-relation of
particular nsSNVs may be incorporated to enable user-defined application scenarios. In
addition, genetic variations have been recognized to affect drug selection, dosing and
adverse events [18]. NsSNV-introduced amino acid substitutions may change existing
binding affinities of a protein or a potential drug target. Hence, the integration of
a workflow for therapeutic use in BALL-SNP to also study interactions of putative
medical substrates and drug targets represents an important extension for furture work.
A database with small ligands and known drugs should be included to test whether
mutations alter known binding affinities by comparing the binding to the unmodified
protein against the binding to the mutated protein. To this end, BALL-SNP may also
assist drug development with respect to individual genetic variations.
Besides nsSNV sets in one gene, we also studied nsSNV combinations in multiple
genes. According to Yue et al., about 25% of nsSNVs are deleterious but not disease-
related [127]. Since proteins with redundant function exist, no noticeable phenotypic
change may be detected when only one involved gene inheres an nsSNV introducing a
dysfunction of the encoded protein [128]. Several in silico prediction tools, however,
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penalize deleterious effects of nsSNVs as disease-associated without considering the
network environment. Due to overlapping protein functions, produced dysfunctions may
be buffered by the environment [129]. In consequence, the analysis of the pathogenic
influence of nsSNV sets in multiple genes requires a multi-scale pipeline to capture
gene-gene environment effects.
In this thesis, we developed an integrative approach based on state-of-the-art patho-
genicity prediction of single nsSNVs, association rule mining, pathway analysis and
subcellular localization of the involved genes. We demonstrated its strength on the
analysis of the DCM data set and a healthy control cohort based on the general
population of the 1000 Genomes Project. Via association rule learning, we detected
associated nsSNV sets in seven genes present in at least 70% of all 639 patient samp-
les, but not in the control cohort. Structural analyses of these revealed primarily an
influence on the protein stability, which agrees with previous studies on nsSNVs [119].
For amino acid substitutions located at the protein surface, we generally observed a
proximity to putative binding pockets. Considering the subcellular localization of the
proteins encoded by the genes harboring the associated nsSNVs, we observed a cascade,
starting from the nucleus, proceeding through the inner cell body to the extracellular
matrix. The performed systematic analysis point to a connection of the identified
genes featuring associated nsSNVs - in functionality as well as in their contribution
to biological pathways. In conclusion, the detected associated nsSNVs may putatively
influence cardiovascular phenotypes. Since statistical relevance not necessarily indicates
clinical relevance, further analyses and experimental validation are required. Despite
cardiovascular diseases, the developed pipeline can likewise be applied to other diseases
such as cancer.
Currently, the data suitable for such multi-scale studies, though, is limited. The majority
of the available classical exome capture studies reveal lower coverage rates compared to
the DCM data. In addition, control cohorts of healthy humans are limited, particularly
in high quality. The interpretation of results obtained by a comparison of data differing
in quality consequently poses a great challenge on the scientific community. Furthermore,
the lack of experimental information often prevents the detection of clinical significance
as well as its validation. Future studies critically rely on advances in high-quality data
generation.
In this thesis, we concentrated on genetic variants in coding regions, in particular
nsSNVs. Beyond these, intronic SNVs in promoter regions and splicing sites as well
as genetic variants in regulatory regions may have an influence on human phenotypes,
since they may affect gene splicing, transcription factor binding and messenger RNA
degradation. In fact, about 88% of genetic variants with weak trait-association from
GWAS represent non-coding variants [130]. The prediction of their pathogenic impact
in silico, however, is even more complex. Their effect, though, is expected to be weaker
compared to coding nsSNVs [131].
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Due to missing computational methods to analyze cumulative nsSNVs and to assess
their impact on pathogenicity, the validation of their clinical relevance is limited. In
fact, genetic testing enables predictive diagnosis and can enhance pre-symptomatic
intervention. Future studies, however, focusing on translation of computational findings
to applicable mechanisms in clinical routine and capturing diagnostic demands, are
highly required.
To improve medical treatment, computational approaches should be designed to address
the requirements in clinical application. An intuitive and, in particular, visual inspection
of genomic data and genetic information might have a greater chance to reach clinical
acceptance, since imaging techniques such as e.g. magnetic resonance tomography
(MRT) have demonstrated their great importance in clinics over the last years. In
addition, the knowledge of individual nsSNV combinations and their functional impact
may pave the way to tailor medical care for patient-specific treatment [132].
In summary, we developed approaches to cover these requirements of computatio-
nal diagnostics within this thesis. We implemented a non-commercial software tool -
BALL-SNP - to promote nsSNV candidate selection by inspection and visualization of
combined genetic and structural information. Although further extensions are required
to assist clinical use of NGS data, BALL-SNP already decisively contributes to existing
instruments of candidate nsSNV analysis. Furthermore, the developed multi-scale ana-
lysis pipeline revealed promising results for the study of DCM patients and may serve
as template for future approaches to identify complex interactions of genes harboring
nsSNVs.
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Appendix: Table of Abbreviations
AA Amino Acid
ATP Adenosine Triphosphate
BALL Biochemical Algorithms Library
BLAST Basic Local Alignment Search Tool
CmPI CELLmicrocosmos 4.2 PathwayIntegration
CTC Circulating Tumor Cell
DCM Dilated Cardiomyopathy
DOPE Discrete Optimized Protein Energy
ExAC Exome Aggregation Consortium
FN False Negatives
FP False Positives
GO Gene Ontology
GUI Graphical User Interface
GWAS Genome-Wide Association Studies
HGMD Human Mutation Database
HMM Hidden Markov Models
KEGG Kyoto Encyclopedia of Genes and Genomes
MT Mutant Type (amino acid)
NMR Nuclear Magnetic Resonance
NIH National Institutes of Health
nsSNV non-synonymous Single Nucleotide Variant
PDB Protein Data Bank
PSIC Position-Specific Independent Counts
PSSM Position-Specific Substitution Matrix
RMSD Root-Mean Square Deviation
SES Solvent-Excluded Surface
SNP Single Nucleotide Polymorphism
SNV Single Nucleotide Variant
subPSEC substitution Position-Specific Evolutionary Conservation
SVM Support Vector Machines
SW Smith-Waterman
TM Transmembrane
TN True Negatives
TP True Positives
UML Unified Modeling Language
VCF Variant Call Format
WT Wild Type (amino acid)
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